10,000 Matching Annotations
  1. Oct 2026
    1. P4F/641Yes11384023260.9NormalNT270

      Case: P4 Female, Korean, 64 years at report

      DiseaseAssertion: VWD1

      FamilyInfo: Positive family history, no details provided.

      ParentalGenotype: NA

      CasePresentingHPOs: HP:0030129, HP:0012147, HP:0030132, HP:0011871

      (Impaired ristocetin cofactor assay activity, Reduced quantity of VWF, Absence of large von Willebrand factor multimers, Impaired RIPA)

      CaseHPOFreeText: bleeding score 11, FVII:C 40%, VWF:Rco 23 IU/dL, VWF:Ag 26 IU/Dl, VWF:Rco/VWF:Ag 0.9, RIPA NT

      CaseNotHPOs: HP:0003645, HP:0001873

      (Prolonged partial thromboplastin time, Thrombocytopenia)

      CaseNotHPOFreeText: aPTT 36s, platelets 270x10^9/L

      CasePreviousTesting: NA

      GenotypingMethod: Direct sequencing of all exons, flanking intronic sequences, and the promoter of VWF was performed.

      Gene: VWF

      Variant: c.3389G>A p.C1130Y

      HGVS: NM_000552.4:c.2574C>G (p.Cys858Trp)

      ClinVar: NA

      CAID: CA232299278

      gnomAD: MAF of 0.0001002 (2/19954 alleles) in the East Asian population

      https://gnomad.broadinstitute.org/variant/12-6143965-G-C

    2. P3

      Case: P3, M/36

      DiseaseAssertion: VWD2A

      FamilyInfo: Positive family history, no details provided.

      ParentalGenotype: NA

      CaseHPOFreeText: The bleeding score was 4, aPTT was 43 seconds, FVIII:C was 22%, VWF:RCo was not determined, and VWF:Ag was 14 IU/dL. The VWF:RCo/VWF:Ag ratio was not available. RIPA showed a loss of intermediate and high molecular weight multimers, VWF multimer analysis was 2, and platelet count was 265 × 10⁹/L.

      CasePreviousTesting: NA

      GenotypingMethod: Direct sequencing of all exons, flanking intronic sequences, and the promoter of VWF was performed.

      Gene: VWF

      Variant: c.3538+1G>A — heterozygous

      HGVS: NM_000552.5(VWF):c.3538+1G>A

      ClinVar: 100267

      CAID: CA228420

      gnomAD: absent from gnomad v4.1.0

    1. large deletion of exons 33–34

      Case: IP-6

      DiseaseAssertion: VWD2

      FamilyInfo: Mother is unaffected carrier of F8 Asn2129Ser. The VWF deletion of exons 33-34 segregates in 5 other affected male family members including the father and a full brother of IP-6. The patient’s father displayed a significant decrease in VWF:Ag and VWF:RCo, 13% and 7%, respectively, FVIII: C of 18.5% and the VWF:RCo/VWF:Ag ratio of 0.5 pointing out to type 2 VWD.

      ParentalGenotype(s): Mother is heterozygous for F8FAsn2129Ser. Father is heterozygous for VWF deletion of exons 33-34.

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag (17%), VWF:RCo (9%) and FVIII:C (1,9%). Bleedings in the oral cavity, ankle joint and hematomas.

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: Direct sequencing of exons 2–52 including exon/intron boundaries of the VWF gene

      GenotypingMethod: multiple ligation‐dependent probe amplification (MLPA; using kit P011 and P012; MRC Holland, Amsterdam, the Netherlands) according to the manufacturer’s instructions. The PCR products were run on an ABI PRISM 3130XL sequencer with the GeneScan 500 LIZ size standard and analyzed using GeneMapper Software 5.0 (Applied Biosystems, Darmstadt, Germany). Dosage analysis based on a comparison between deleted and reference wild‐type DNA samples was performed using the Excel‐based software Coffalyser V9.4 (MRC Holland).

      PreviouslyPublished: NA

      Gene:VWF

      Variant: deletion of exons 33-34

      HGVS:

      ClinVarID:

      CAID:

      gnomAD:

      MultipleGeneVariants:

      GeneName: F8

      Variant: Asn2129Ser

      ClinVarID or CAID:

      gnomAD:

    1. 3.1 Description of the study population

      Patient4: IOPD Group, 12 days old

      CasePresentingHPOs:

      HPOsFreeText: LDH = 432 U/L, CK = 458 U/L, ALT = 37 U/L, AST = 80 U/L, Mann-Whitney Test = 3

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.3:c.872T>C

      CAID: CA401363854, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA401363854

      gnomAD: n/a

      Variant2: NM_000152.4(GAA):c.1935C>A (p.Asp645Glu)

      ClinVar: 4029, https://www.ncbi.nlm.nih.gov/clinvar/variation/4029/

      gnomAD: 0.0001240, https://gnomad.broadinstitute.org/variant/17-78086721-C-A

    2. 3.1 Description of the study population

      Patient2: IOPD Group, 10days old

      CasePresentingHPOs:

      HPOsFreeText: LDH = 516 U/L, CK = 385 U/L, ALT = 12 U/L, AST = 73 U/L, Mann-Whitney Test = 2

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant: NM_000152.4(GAA):c.1935C>A (p.Asp645Glu)

      ClinVar: 4029, https://www.ncbi.nlm.nih.gov/clinvar/variation/4029/

      gnomAD: 0.0001240, https://gnomad.broadinstitute.org/variant/17-78086721-C-A

    3. 3.1 Description of the study population

      Patient8: IOPD Group, 12days old

      CasePresentingHPOs:

      HPOsFreeText: LDH = 418 U/L, CK = 483 U/L, ALT = 44 U/L, AST = 93 U/L, Mann-Whitney Test = 2

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant: NM_000152.4(GAA):c.1935C>A (p.Asp645Glu)

      ClinVar: 4029, https://www.ncbi.nlm.nih.gov/clinvar/variation/4029/

      gnomAD: 0.0001240, https://gnomad.broadinstitute.org/variant/17-78086721-C-A

    1. 48 U

      Case: Patient 48, Family U (Table 1.), M/43, Afro-Caribbean

      DiseaseAssertion: VWD2M

      FamilyInfo: Patient 43 (M/10, Afro-Caribbean), Patient 44 (M/15, Afro-Caribbean), Patient 46 (M/47, Afro-Caribbean) and Patient 47 (M/78, Afro Caribbean) also from Family U. (Table 1.)

      ParentalGenotype(s): NA

      CasePresentingHPOs:

      CaseHPOFreeRext: BAT = 4, FVIII:C (IU/dL) = 32, VWF:Ag (IU/dL) = 25, VWF:Act (IU/dL) = 21

      CaseNOTHPOs:

      CaseNOTHPOFreeText: Blood group AB+

      CasePreviousTesting:

      GenotypingMethod: All samples were analyzed by captured-based high throughput sequencing which was performed with a custom-design of the VWF gene provided by Twist BioScience (San Francisco, USA). It comprised all 52 exons, intronic flanking regions, promoter and 3’UTR region of the VWF gene. Libraries were prepared by using the Twist NGS target enrichment solution (Twist BioScience) according to the manufacturer protocol. Samples were analyzed on a NovaSeq 6000 sequencer (Illumina) with a median read depth of 2500X by using the 300-cycle S1 NovaSeq 6000seq reagent kit with 150-bp paired-end reads. The raw data were analyzed with Mutect21 and Vardict2 tools. The inhouse NGSreport software (CHU Lille) was used for data visualization, sequences check and conservation of variants with high quality metrics. In some cases, patients genomic DNA was screened for sequence variations (large deletions, insertions and duplications) by Multiplex Ligation-dependent Probe Amplification (MCR Holland).

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3943C > T p.(Arg1315Cys)

      HGVS: NM_000552.5:c.3943C>T (p.Arg1315Cys)

      ClinVarID: 100310

      CAID: CA228502

      gnomAD: MAF of 8.476e-7 (1/ 1179850 alleles) in European population https://gnomad.broadinstitute.org/variant/chr12-6019161-A-C?dataset=gnomad_r4

    2. 47 U

      Case: Patient 47, Family U (Table 1.), M/78, Afro-Caribbean

      DiseaseAssertion: VWD2M

      FamilyInfo: Patient 43 (M/10, Afro-Caribbean), Patient 44 (M/15, Afro-Caribbean), Patient 46 (M/47, Afro-Caribbean) and Patient 48 (M/43, Afro Caribbean) also from Family U. (Table 1.)

      ParentalGenotype(s): NA

      CasePresentingHPOs:

      CaseHPOFreeRext: BAT = 4, FVIII:C (IU/dL) = 11, VWF:Ag (IU/dL) = 20, VWF:Act (IU/dL) = 12.6

      CaseNOTHPOs:

      CaseNOTHPOFreeText: Blood group B+

      CasePreviousTesting:

      GenotypingMethod: All samples were analyzed by captured-based high throughput sequencing which was performed with a custom-design of the VWF gene provided by Twist BioScience (San Francisco, USA). It comprised all 52 exons, intronic flanking regions, promoter and 3’UTR region of the VWF gene. Libraries were prepared by using the Twist NGS target enrichment solution (Twist BioScience) according to the manufacturer protocol. Samples were analyzed on a NovaSeq 6000 sequencer (Illumina) with a median read depth of 2500X by using the 300-cycle S1 NovaSeq 6000seq reagent kit with 150-bp paired-end reads. The raw data were analyzed with Mutect21 and Vardict2 tools. The inhouse NGSreport software (CHU Lille) was used for data visualization, sequences check and conservation of variants with high quality metrics. In some cases, patients genomic DNA was screened for sequence variations (large deletions, insertions and duplications) by Multiplex Ligation-dependent Probe Amplification (MCR Holland).

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3943C > T p.(Arg1315Cys)

      HGVS: NM_000552.5:c.3943C>T (p.Arg1315Cys)

      ClinVarID: 100310

      CAID: CA228502

      gnomAD: MAF of 8.476e-7 (1/ 1179850 alleles) in European population https://gnomad.broadinstitute.org/variant/chr12-6019161-A-C?dataset=gnomad_r4

      Variant: c.4196G > A, p.(Arg1399His)

      HGVS: NM_000552.5:c.4196G>A (p.Arg1399His)

      ClinVarID: 293

      CAID: CA114133

      gnomAD: MAF of 0.01540 (456/29604 alleles) in Ashkenazi Jewish population https://gnomad.broadinstitute.org/variant/chr12-6019222-C-T?dataset=gnomad_r4

    3. 62 M

      Case: Patient 62, Family M (Table 1.), F/42, Afro-Caribbean

      DiseaseAssertion: VWD3

      FamilyInfo: Patient 20 (M/80, Afro-Caribbean) also in Family M. (Table 1.)

      ParentalGenotype(s): NA

      CasePresentingHPOs:

      CaseHPOFreeRext: BAT =32, FVIII:C (IU/dL) = 2, VWF:Ag (IU/dL) = 5, VWF:Act (IU/dL) = 5

      CaseNOTHPOs:

      CaseNOTHPOFreeText: Blood group O+

      CasePreviousTesting:

      GenotypingMethod: All samples were analyzed by captured-based high throughput sequencing which was performed with a custom-design of the VWF gene provided by Twist BioScience (San Francisco, USA). It comprised all 52 exons, intronic flanking regions, promoter and 3’UTR region of the VWF gene. Libraries were prepared by using the Twist NGS target enrichment solution (Twist BioScience) according to the manufacturer protocol. Samples were analyzed on a NovaSeq 6000 sequencer (Illumina) with a median read depth of 2500X by using the 300-cycle S1 NovaSeq 6000seq reagent kit with 150-bp paired-end reads. The raw data were analyzed with Mutect21 and Vardict2 tools. The inhouse NGSreport software (CHU Lille) was used for data visualization, sequences check and conservation of variants with high quality metrics. In some cases, patients genomic DNA was screened for sequence variations (large deletions, insertions and duplications) by Multiplex Ligation-dependent Probe Amplification (MCR Holland).

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.1530G > A, p.(Val510 =)

      HGVS: NM_000552.5:c.1530G>A (p.Val510=)

      ClinVarID:

      CAID: CA6403368

      gnomAD: MAF of 0.00002198 (2/91004 alleles) in South Asian population https://gnomad.broadinstitute.org/variant/chr12-6062957-C-T?dataset=gnomad_r4

      Variant: c.1892C > T, p.(Ala631Val)

      HGVS: NM_000552.5:c.1892C>T (p.Ala631Val)

      ClinVarID: 422844

      CAID: CA6403245

      gnomAD: MAF of 0.001908 (137/71810 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6056910-G-A?dataset=gnomad_r4

      Variant: c.2220G > A, p.(Met740Ile)

      HGVS: NM_000552.5:c.2220G>A (p.Met740Ile)

      ClinVarID: 100206

      CAID: CA201316

      gnomAD: MAF of 0.1816 (13626/75022 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6046784-C-T?dataset=gnomad_r4

      Variant: c.2451T > A, p.(His817Gln)

      HGVS: NM_000552.5:c.2451T>A (p.His817Gln)

      ClinVarID: 100224

      CAID: CA228345

      gnomAD: MAF of 0.1150 (8626/75016 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6036483-A-T?dataset=gnomad_r4

      Variant: c.3445T > C, p.(Cys1149Arg)

      HGVS: NM_000552.5:c.3445T>C (p.Cys1149Arg)

      ClinVarID: 309

      CAID: CA228410

      gnomAD: MAF of 0.000003160 (1/316464 alleles) in European (non-Finnish) population https://gnomad.broadinstitute.org/variant/chr12-6022833-A-G?dataset=gnomad_r4

      Variant: c.4414G > C p.(Asp1472His)

      HGVS: NM_000552.5:c.4414G>C (p.Asp1472His)

      ClinVarID: 256679

      CAID: CA6402534

      gnomAD: MAF of 0.5076 (38011/74882 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6019004-C-G?dataset=gnomad_r4

      Variant: c.6554G > A, p.(Arg2185Gln)

      HGVS: NM_000552.5:c.6554G>A (p.Arg2185Gln)

      ClinVarID: 100443

      CAID: CA228748

      gnomAD: MAF of 0.1927 (14427/74878 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-5993906-C-T?dataset=gnomad_r4

      Variant: c.6432dupA, (Pro2145Thrfs*5)

      HGVS: NM_000552.5:c.6432dup (p.Pro2145Thrfs*5)

      ClinVarID:

      CAID: CA603482896

      gnomAD: MAF of 0.00001333 (1/75038 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-5994027-G-GT?dataset=gnomad_r4

    4. 22 I

      Case: Patient 22, Family I (Table 1.), F/67, Afro-Caribbean

      DiseaseAssertion: VWD2A (IIE)

      FamilyInfo: Patient 13 (F/65, Afro-Caribbean), Patient 21 (F/97, Afro-Caribbean), Patient 23 (F/86, Afro-Caribbean), Patient 24 (F/92, Afro-Caribbean), Patient 25 (F/62, Afro-Carribean) also from Family I. (Table 1.)

      ParentalGenotype(s): NA

      CasePresentingHPOs:

      CaseHPOFreeRext: BAT =2, FVIII:C (IU/dL) = 33, VWF:Ag (IU/dL) = 20, VWF:Act (IU/dL) = 17

      CaseNOTHPOs:

      CaseNOTHPOFreeText: Blood group B+

      CasePreviousTesting:

      GenotypingMethod: All samples were analyzed by captured-based high throughput sequencing which was performed with a custom-design of the VWF gene provided by Twist BioScience (San Francisco, USA). It comprised all 52 exons, intronic flanking regions, promoter and 3’UTR region of the VWF gene. Libraries were prepared by using the Twist NGS target enrichment solution (Twist BioScience) according to the manufacturer protocol. Samples were analyzed on a NovaSeq 6000 sequencer (Illumina) with a median read depth of 2500X by using the 300-cycle S1 NovaSeq 6000seq reagent kit with 150-bp paired-end reads. The raw data were analyzed with Mutect21 and Vardict2 tools. The inhouse NGSreport software (CHU Lille) was used for data visualization, sequences check and conservation of variants with high quality metrics. In some cases, patients genomic DNA was screened for sequence variations (large deletions, insertions and duplications) by Multiplex Ligation-dependent Probe Amplification (MCR Holland).

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.1530G > A, p.(Val510 =) p.

      HGVS: NM_000552.5:c.1530G>A (p.Val510=)

      ClinVarID:

      CAID: CA6403368

      gnomAD: MAF of 0.00002198 (2/91004 alleles) in South Asian population https://gnomad.broadinstitute.org/variant/chr12-6062957-C-T?dataset=gnomad_r4

      Variant: c.1892C > T, p.(Ala631Val)

      HGVS: NM_000552.5:c.1892C>T (p.Ala631Val)

      ClinVarID: 422844

      CAID: CA6403245

      gnomAD: MAF of 0.001908 (137/71810 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6056910-G-A?dataset=gnomad_r4

      Variant: c.2220G > A, p.(Met740Ile)

      HGVS: NM_000552.5:c.2220G>A (p.Met740Ile)

      ClinVarID: 100206

      CAID: CA201316

      gnomAD: MAF of 0.1816 (13626/75022 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6046784-C-T?dataset=gnomad_r4

      Variant: c.2451T > A, p.(His817Gln)

      HGVS: NM_000552.5:c.2451T>A (p.His817Gln)

      ClinVarID: 100224

      CAID: CA228345

      gnomAD: MAF of 0.1150 (8626/75016 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6036483-A-T?dataset=gnomad_r4

      Variant: c.3258C > T, p.(Tyr1086 =)

      HGVS: NM_000552.5:c.3258C>T (p.Tyr1086=)

      ClinVarID: 256664

      CAID: CA6402788

      gnomAD: MAF of 0.1284 (9131/71128 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6023752-G-A?dataset=gnomad_r4

      Variant: c.3445T > C, p.(Cys1149Arg)

      HGVS: NM_000552.5:c.3445T>C (p.Cys1149Arg)

      ClinVarID: 309

      CAID: CA228410

      gnomAD: MAF of 0.000003160 (1/316464 alleles) in European (non-Finnish) population https://gnomad.broadinstitute.org/variant/chr12-6022833-A-G?dataset=gnomad_r4

      Variant: c.4414G > C p.(Asp1472His)

      HGVS: NM_000552.5:c.4414G>C (p.Asp1472His)

      ClinVarID: 256679

      CAID: CA6402534

      gnomAD: MAF of 0.5076 (38011/74882 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-6019004-C-G?dataset=gnomad_r4

      Variant: c.6554G > A, p.(Arg2185Gln)

      HGVS: NM_000552.5:c.6554G>A (p.Arg2185Gln)

      ClinVarID: 100443

      CAID: CA228748

      gnomAD: MAF of 0.1927 (14427/74878 alleles) in African/African American population https://gnomad.broadinstitute.org/variant/chr12-5993906-C-T?dataset=gnomad_r4

    5. 46 U

      Case: Patient 46, Family U (Table 1.), M/47, Afro-Caribbean

      DiseaseAssertion: VWD2M

      FamilyInfo: Patient 43 (M/10, Afro-Caribbean), Patient 44 (M/15, Afro-Caribbean), Patient 47(M/78, Afro-Caribbean) and Patient 48 (M/43, Afro Caribbean) also from Family U. (Table 1.)

      ParentalGenotype(s): NA

      CasePresentingHPOs:

      CaseHPOFreeRext: BAT = 11, FVIII:C (IU/dL) = 35.2, VWF:Ag (IU/dL) = 22, VWF:Act (IU/dL) = 8

      CaseNOTHPOs:

      CaseNOTHPOFreeText: Blood group A+

      CasePreviousTesting:

      GenotypingMethod: All samples were analyzed by captured-based high throughput sequencing which was performed with a custom-design of the VWF gene provided by Twist BioScience (San Francisco, USA). It comprised all 52 exons, intronic flanking regions, promoter and 3’UTR region of the VWF gene. Libraries were prepared by using the Twist NGS target enrichment solution (Twist BioScience) according to the manufacturer protocol. Samples were analyzed on a NovaSeq 6000 sequencer (Illumina) with a median read depth of 2500X by using the 300-cycle S1 NovaSeq 6000seq reagent kit with 150-bp paired-end reads. The raw data were analyzed with Mutect21 and Vardict2 tools. The inhouse NGSreport software (CHU Lille) was used for data visualization, sequences check and conservation of variants with high quality metrics. In some cases, patients genomic DNA was screened for sequence variations (large deletions, insertions and duplications) by Multiplex Ligation-dependent Probe Amplification (MCR Holland).

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3943C > T p.(Arg1315Cys)

      HGVS: NM_000552.5:c.3943C>T (p.Arg1315Cys)

      ClinVarID: 100310

      CAID: CA228502

      gnomAD: MAF of 8.476e-7 (1/ 1179850 alleles) in European population https://gnomad.broadinstitute.org/variant/chr12-6019161-A-C?dataset=gnomad_r4

    1. I : 1

      Case#: F5, I:1

      DiseaseAssertion: Type 2 VWD

      CaseHPOFreeText: all mutimers present, VWF:Ag = 105; VWF:RCo = 90; VWF:GPIbM = 87; 0.86; 0.82; 0.96

      CasePreviousTesting: Not clearly described

      Gene: VWF

      Variant: p.[I1372S];[=]

      HGVS: c.4115T>G (p.Ile1372Ser)

      CAID: CA228535

      gnomAD: https://gnomad.broadinstitute.org/variant/12-6019303-A-C?dataset=gnomad_r4

    2. I : 1

      Case#: F18, I:1

      DiseaseAssertion: Type 2 VWD

      CaseHPOFreeText: loss of high and intermediate MWMs, VWF:Ag = 95; VWF:RCo = 30; VWF:GPIbM = 70; 0.32; 0.73; 2.31

      CasePreviousTesting: Not clearly described

      Gene: VWF

      Variant: p.[R1308C];[=]

      HGVS: c.3922C>T (p.Arg1308Cys)

      CAID: CA114125

      gnomAD: absent from gnomad v4.1.0

    3. I : 1

      Case#: F17, I:1

      DiseaseAssertion: Type 2 VWD

      CaseHPOFreeText: loss of high and intermediate MWMs, VWF:Ag = 30; VWF:RCo = 8; VWF:GPIbM = 23; 0.27; 0.75; 2.81

      CasePreviousTesting: Not clearly described

      Gene: VWF

      Variant: p.[R1308C];[=]

      HGVS: c.3922C>T (p.Arg1308Cys)

      CAID: CA114125

      gnomAD: absent from gnomad v4.1.0

    4. I : 1

      Case#: F16, I:1

      DiseaseAssertion: Type 2 VWD

      CaseHPOFreeText: loss of high and intermediate MWMs, VWF:Ag = 48; VWF:RCo = 13; VWF:GPIbM = 48; 0.27; 1.00; 3.65

      CasePreviousTesting: Not clearly described

      Gene: VWF

      Variant: p.[R1308C];[=]

      HGVS: c.3922C>T (p.Arg1308Cys)

      CAID: CA114125

      gnomAD: absent from gnomad v4.1.0

    5. I : 1

      Case#: F15, I:1

      DiseaseAssertion: Type 2 VWD

      CaseHPOFreeText: loss of high and intermediate MWMs, VWF:Ag = 43; VWF:RCo = 12; VWF:GPIbM = 30; 0.28; 0.70; 2.56

      CasePreviousTesting: Not clearly described

      Gene: VWF

      Variant: p.[R1308C];[=]

      HGVS: c.3922C>T (p.Arg1308Cys)

      CAID: CA114125

      gnomAD: absent from gnomad v4.1.0

    6. II : 2

      Case#: F14, II:2

      DiseaseAssertion: Type 2 VWD

      CaseHPOFreeText: loss of high and intermediate MWMs, VWF:Ag = 12; VWF:RCo = 3; VWF:GPIbM = 9; 0.21; 0.71; 3.31

      CasePreviousTesting: Not clearly described

      Gene: VWF

      Variant: p.[C275R];[P1337L]

      HGVS: c.823T>C (p.Cys275Arg), c.4010C>T (p.Pro1337Leu)

      CAID: CA228836, CA228510

      gnomAD: absent from gnomad, https://gnomad.broadinstitute.org/variant/12-6019408-G-A?dataset=gnomad_r4

    1. An infant with presumed maternal immune thrombocytopenic purpura had persistent thrombocytopenia with platelet clumping. The patient had no significant bleeding symptoms in the first year of life and von Willebrand antigen and ristocetin cofactor activity were normal. Absent high molecular weight multimers ultimately led to a genetically proven diagnosis of type 2B von Willebrand disease (3964G>A VWF exon 28), highlighting the challenges of establishing this diagnosis in infants.

      Case: Rotz Proband, female, reported at birth

      DiseaseAssertion: VWD2b

      FamilyInfo: Mother was 30yo reported with new onset thrombocytopenia during labor, diagnosed with maternal ITP; mother also had history of menorrhagia and excessive bleeding with minor trauma; VWF profile revealed a Factor VIII activity=49 IU/dL, VWF antigen=32 IU/dL, and undetectable RCo

      ParentalGenotype(s): mother also carried c.3964G>A unregistered variant

      CasePresentingHPOs: HP:0001873, HP:0030132, HP:0000967, HP:0000421, HP:0001892, HP:0001903, HP:0001981

      (thrombocytopenia, Absence of large von Willebrand factor multimers, Petechiae, epistaxis, abnormal bleeding, anemia, schistocyte)

      CaseHPOFreeText: small hematoma at IV puncture site, platelet count was 9×109/L, ultrasound showed no hemorrhage, hemoglobin=7.6 g/dL

      CaseNOTHPOs: HP:0012147, HP:0030129

      (Reduced quantity of VWF, impaired ristocetin cofactor assay activity)

      CaseNOTHPOFreeText: no unusual findings on physical exam

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of VWF exon 28

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3964G>A unregistered variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

    1. 7

      Case: Patient 7 (Family B), male, 81yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0030132, HP:0030129, HP:0030130, HP:0011871

      (Absence of large von Willebrand factor multimers, impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity, Impaired RIPA)

      CaseHPOFreeText: blood group A, Platelet count x103/μl = 165, PFA 100 sec = >300, SPA % = NA, MADR mg/mL = 0.6, VWF:Ag U/dL = 166.4, VWF:CB U/dL = 30.0, VWF:CB ratio = 0.18, VWF:RCo U/dL = 112.0, VWF:RCo ratio = 0.67, Platelet VWF U/dL = NA, FVIII U/dL = 136.0, BAT F/M = NA

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of exon 28 of VWF

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3922C>T (p.Arg1308Cys)

      HGVS: NM_000552.4(VWF):c.3922C>T (p.Arg1308Cys)

      ClinVarID: 289; https://www.ncbi.nlm.nih.gov/clinvar/variation/289/

      CAID: NA

      gnomAD: absent

    2. 17

      Case: Patient 17 (Family E), female, 24yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0030132, HP:0030129, HP:0030130, HP:0011871, HP:0012147

      (Absence of large von Willebrand factor multimers, impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity, Impaired RIPA, Reduced quantity of VWF)

      CaseHPOFreeText: blood group O, Platelet count x103/μl = 65, PFA 100 sec = >300, SPA % = 22.5, MADR mg/mL = 0.15, VWF:Ag U/dL = 35.9, VWF:CB U/dL = 15.6, VWF:CB ratio = 0.44, VWF:RCo U/dL = 14.4, VWF:RCo ratio = 0.40, Platelet VWF U/dL = 140.3, FVIII U/dL = 35.9, BAT F/M = 13

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of exon 28 of VWF

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3946G>A (p.Val1316Met)

      HGVS: NM_000552.4(VWF):c.3946G>A (p.Val1316Met)

      ClinVarID: 290; https://www.ncbi.nlm.nih.gov/clinvar/variation/290/

      CAID: NA

      gnomAD: absent

    3. 4

      Case: Patient 4 (Family A), male, 43yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0030132, HP:0030129, HP:0030130, HP:0011871, HP:0012147

      (Absence of large von Willebrand factor multimers, impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity, Impaired RIPA, Reduced quantity of VWF)

      CaseHPOFreeText: blood group A, Platelet count x103/μl = 163, PFA 100 sec = >300, SPA % = 0, MADR mg/mL = 0.6, VWF:Ag U/dL = 42.8, VWF:CB U/dL = 10.6, VWF:CB ratio = 0.25, VWF:RCo U/dL = 25.2, VWF:RCo ratio = 0.58, Platelet VWF U/dL = 132.7, FVIII U/dL = 47.1, BAT F/M = 10

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of exon 28 of VWF

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3922C>T (p.Arg1308Cys)

      HGVS: NM_000552.4(VWF):c.3922C>T (p.Arg1308Cys)

      ClinVarID: 289; https://www.ncbi.nlm.nih.gov/clinvar/variation/289/

      CAID: NA

      gnomAD: absent

    1. Case#: Elayaperumal_2018_V-225 , M, 1 month (onset), origin in India

      DiseaseAssertion: VWD type 3

      FamilyInfo: consanguinity not reported, family history negative

      ParentalGenotype: not reported

      CasePresentingHPOs:

      CaseHPOFreeText: bleeding score 16, VWF:Ag 0, FVIII:C 4.1%

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting: not reported

      GenotypingMethod: CSGE and Sanger sequencing of VWF gene only.

      Gene: VWF

      Variant: homozygous c.1117C>T (p.Arg373*)

      HGVS: NM_000552.3:c.1117C>T

      ClinVarID: 100175

      CAID: CA228261

      gnomAD: Popmax (0.00004448 ) in the south Asian population (4/30550 alleles). 0 homozygotes reported.

      MultipleGeneVariants:

    2. Case#: Elayaperumal_2018_V-270 , F, 1.5 y.o. (onset), origin in India

      DiseaseAssertion: VWD type 3

      FamilyInfo: consanguinity, no family history of bleeding

      ParentalGenotype: not reported

      CasePresentingHPOs:

      CaseHPOFreeText: bleeding score of 3, VWF:Ag of 0, FVIII:C 6.2%

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting: not reported

      GenotypingMethod: CSGE and Sanger sequencing of VWF gene only.

      Gene: VWF

      Variant: homozygous c.3656delC (p.Pro1219Leufs*34)

      HGVS: NM_000552.3:c.3656delC

      ClinVarID: not found

      CAID:unable to register- system not processing 2/3/23

      gnomAD: not found

      MultipleGeneVariants: n/a

    3. Case#: Elayaperumal_2018_V-307 , F, 1 y.o. (onset), origin in India

      DiseaseAssertion: VWD type 3

      FamilyInfo: consanguinity reported. family history negative

      ParentalGenotype: not reported

      CasePresentingHPOs:

      CaseHPOFreeText: Bleeding score 4, VWF:Ag 0, FVIII:C 1.6%

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting: not reported

      GenotypingMethod: CSGE and Sanger sequencing of VWF gene only.

      Gene: VWF

      Variant: homozygous c.2443-1G>C

      HGVS: NM_000552.3:c.2443-1G>C

      ClinVarID: 100222

      CAID: CA228342

      gnomAD: Popmax (-). MAF 0.000008796 (1/113692) in the European (non-Finnish) population. No homozygotes reported.

      MultipleGeneVariants:

    4. Case#: Elayaperumal_2018_V-282, F, 2 y.o. (onset), origin in India

      DiseaseAssertion: VWD type 3

      FamilyInfo: reportedly not-consanguineous. No family history of bleeding.

      ParentalGenotype: not reported

      CasePresentingHPOs:

      CaseHPOFreeText: bleeding score of 17, VWF:Ag of 0, FVIII:C 4.3%

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting: not reported

      GenotypingMethod: CSGE and Sanger sequencing of VWF gene only.

      Gene: VWF

      Variant: heterozygous c.2683C>T (Gln895), c.3835G>A (p.Val1279Ile), c.3931C>T (p.Gln1311)

      HGVS: NM_000552.3:c.2683C>T, NM_000552.3:c.3835G>A, NM_000552.3:c.3931C>T

      ClinVarID: -,100288,100307

      CAID: -, CA228459, CA228496

      gnomAD: 1: not found 2: MAF of 0.002604 (27/10370 allele, Ashkenazi Jewish) https://gnomad.broadinstitute.org/variant/12-6128749-C-T?dataset=gnomad_r2_1 3:

      MultipleGeneVariants:

    1. 051

      Case: Patient ID 051 (green color code), 11 year old Black female, not Hispanic

      DiseaseAssertion: Type 3 Von Willebrand Disease

      CasePresentingHPOs: HP:6000676

      (Anti-von Willebrand factor antibody positivity)

      CaseHPOFreeRext: ISTH-BAT bleeding score of 32

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: N/A

      GenotypingMethod: Full-length VWF exonic Sanger sequencing and array comparative genomic hybridization to detect deletions or duplications

      Gene: VWD

      HGVS: NM_000552.5

      Variant1: p.Trp1144*

      ClinVarID / CAID: None

      Variant2: p.Leu1281Cysfs*16

      CAID: CA2575053893

      gnomAD: MAF of 1.695E-6 in European (non-Finnish), no homozygotes noted; gnomAD Page

    1. Case: P24, Chinese, male, 6yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type A blood, bleeding score = 13; VWF:Ag (%) = 0.9, VWF:RCo (%) = 0.7, FVIII:C (%) = 5.0, VWF:CB (%) = 0.7, VWFpp (%) = 0.9, VWF:RCo/VWF:Ag = 0.8, VWF:CB/VWF:Ag = 0.8, VWFpp/VWF:Ag = 1.0, FVIII:C/VWF:Ag = 5.6

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.478G>C (p.Gly160Arg)

      HGVS: NM_000552.5:c.478G>C (p.Gly160Arg)

      ClinVarID: NA

      CAID: CA383518174; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383518174

      gnomAD: absent

    2. Case: P59, Chinese, female, 7yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 7; VWF:Ag (%) = 1.4, VWF:RCo (%) = 1.0, FVIII:C (%) = 3.9, VWF:CB (%) = 1.3, VWFpp (%) = 1.2, VWF:RCo/VWF:Ag = 0.7, VWF:CB/VWF:Ag = 0.9, VWFpp/VWF:Ag = 0.9, FVIII:C/VWF:Ag = 2.8

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.2964C>A (p.Tyr988Ter)

      HGVS: NM_000552.5:c.2964C>A (p.Tyr988Ter)

      ClinVarID: NA

      CAID: CA383516120; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383516120

      gnomAD: absent

      Variant 2: c.6540T>G (p.Tyr2180Ter)

      HGVS: NM_000552.5:c.6540T>G (p.Tyr2180Ter)

      ClinVarID: NA

      CAID: CA383490834; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383490834

      gnomAD: absent

    3. Case: P30, Chinese, female, 16yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 21; VWF:Ag (%) = 0.5, VWF:RCo (%) = <0.5, FVIII:C (%) = 2.0, VWF:CB (%) = 0.6, VWFpp (%) = <0.5`, VWF:RCo/VWF:Ag = NA, VWF:CB/VWF:Ag = 1.2, VWFpp/VWF:Ag = NA, FVIII:C/VWF:Ag = 4.0

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: Exons 6–16 del - unregistered variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

    4. Case: P89, Chinese, female, 51yo

      DiseaseAssertion: VWD2N

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 7; VWF:Ag (%) = 125.8, VWF:RCo (%) = 119.6, FVIII:C (%) = 9.8, VWF:CB (%) = 127.8, VWFpp (%) = 109.8, VWF:RCo/VWF:Ag = 1.0, VWF:CB/VWF:Ag = 1.0, VWFpp/VWF:Ag = 0.9, FVIII:C/VWF:Ag = 0.1, VWF: FVIIIB (%) = 0.1

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.2446C>T (p.Arg816Trp)

      HGVS: NM_000552.4(VWF):c.2446C>T (p.Arg816Trp)

      ClinVarID: 295; https://www.ncbi.nlm.nih.gov/clinvar/variation/295/

      CAID: NA

      gnomAD: MAF = 0.0002541 (9/35418 alleles) in the Latino/Admixed American population; https://gnomad.broadinstitute.org/variant/12-6145654-G-A?dataset=gnomad_r2_1

    5. Case: P28, Chinese, male, 15yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type A blood, bleeding score = 4; VWF:Ag (%) = 17.7, VWF:RCo (%) = 4.9, FVIII:C (%) = 25.5, VWF:CB (%) = 5.1, VWFpp (%) = 45.3, VWF:RCo/VWF:Ag = 0.3, VWF:CB/VWF:Ag = 0.3, VWFpp/VWF:Ag = 2.6, FVIII:C/VWF:Ag = 1.4, RIPA (0.5 mg/ml, %) = 20.5, PLT(×109/l) = 112

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3922C>T (p.Arg1308Cys)

      HGVS: NM_000552.4(VWF):c.3922C>T (p.Arg1308Cys)

      ClinVarID: 289; https://www.ncbi.nlm.nih.gov/clinvar/variation/289/

      CAID: NA

      gnomAD: absent

    6. Case: P47, Chinese, female, 23yo

      DiseaseAssertion: VWD1

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 12; VWF:Ag (%) = 4.5, VWF:RCo (%) = 3.3, FVIII:C (%) = 36.5, VWF:CB (%) = 4.2, VWFpp (%) = 5.3, VWF:RCo/VWF:Ag = 0.7, VWF:CB/VWF:Ag = 0.9, VWFpp/VWF:Ag = 1.2, FVIII:C/VWF:Ag = 8.1, RIPA (1.2 mg/ml, %) = 55.9

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.100C>T (p.Arg34Ter)

      HGVS: NM_000552.4(VWF):c.100C>T (p.Arg34Ter)

      ClinVarID: 100171; https://www.ncbi.nlm.nih.gov/clinvar/variation/100171/

      CAID: NA

      gnomAD: MAF = 0.00002645 (3/113436 alleles) in the European (non-Finnish) population; https://gnomad.broadinstitute.org/variant/12-6230460-G-A?dataset=gnomad_r2_1

      Variant 2: c.6860G>A (p.Arg2287Gln)

      HGVS: NM_000552.3:c.6860G>A (p.Arg2287Gln)

      ClinVarID: NA

      CAID: CA6401877; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA6401877

      gnomAD: MAF = 0.005415 (108/19946 alleles) in the East Asian population; https://gnomad.broadinstitute.org/variant/12-6094770-C-T

    7. Case: P8, Chinese, male 3yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type A blood, bleeding score = 5; VWF:Ag (%) = 2.1, VWF:RCo (%) = 1.7, FVIII:C (%) = 4.8, VWF:CB (%) = 1.5, VWFpp (%) = 2.3, VWF:RCo/VWF:Ag = 0.8, VWF:CB/VWF:Ag = 0.7, VWFpp/VWF:Ag = 1.1, FVIII:C/VWF:Ag = 2.3

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.1025_1032dup - unregistered variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

      Variant 2: c.7969C>T (p.Gln2657Ter)

      HGVS: NM_000552.5:c.7969C>T (p.Gln2657Ter)

      ClinVarID: NA

      CAID: CA383487678; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383487678

      gnomAD: NA

    8. Case: P81, Chinese, female, 30yo

      DiseaseAssertion: VWD1

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type A blood, bleeding score = 7; VWF:Ag (%) = 5.0, VWF:RCo (%) = 5.3, FVIII:C (%) = 6.1, VWF:CB (%) = 6.8, VWFpp (%) = 46.0, VWF:RCo/VWF:Ag = 1.1, VWF:CB/VWF:Ag = 1.4, VWFpp/VWF:Ag = 9.2, FVIII:C/VWF:Ag = 1.2, RIPA (1.2 mg/ml, %) = 85.4

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3614G>A (p.Arg1205His)

      HGVS: NM_000552.4(VWF):c.3614G>A (p.Arg1205His)

      ClinVarID: 308; https://www.ncbi.nlm.nih.gov/clinvar/variation/308/

      CAID: NA

      gnomAD: absent

    1. rs617485116131999c.3445T > C26p.C1149R1042A

      Case: n.a.

      DiseaseAssertion: VWD 2A

      FamilyInfo:n.a.

      ParentalGenotype(s):n.a.

      CasePresentingHPOs:n.a.

      CaseHPOFreeRext:n.a.

      CaseNOTHPOs: n.a.

      CaseNOTHPOFreeText:n.a.

      CasePreviousTesting:n.a.

      GenotypingMethod:n.a.

      PreviouslyPublished: If applicable.n.a.

      Gene: VWF

      Variant:NM_000552.5(VWF):c.3445T>C (p.Cys1149Arg)

      HGVS:NM_000552.5:c.3445T>C

      ClinVarID:309

      CAID:n.a.

      gnomAD:n.a.

    1. P9

      Case: P9, female, 28yo

      DiseaseAssertion: VWD2M

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147, HP:0030129, HP:0030130

      (Reduced quantity of VWF, Impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity)

      CaseHPOFreeText: bleeding score = 7; VWF:Ag (%) = 35, VWF:RCo(%) = 24, VWF:RCo/VWF:Ag ratio = 0.69, VWF:CIIIB (%) = 11, VWF:CIIIB/VWF:Ag ratio = 0.31, VWF:CVIB (%) = 19.2, VWF:CVIB/VWF:Ag ratio = 0.54

      CaseNOTHPOs: HP:0030132

      (Absence of large von Willebrand factor multimers)

      CaseNOTHPOFreeText: NA

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.5140G>C (p.Ala1714Pro)

      HGVS: NM_000552.3:c.5140G>C (p.Ala1714Pro)

      ClinVarID: NA

      CAID: CA383496428; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383496428

      gnomAD: absent

    1. 48 2.5 M 19 c.2443-1G.C Hmz 2.5 ,1 6 - -

      Case: 48, M, 2.5 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: no family history of disease, Consanguinity: no

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): 2.5, VWF:Ag (U/dl): <1, Bleeding Score: 6

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.2443-1G>C, Exon 19

      Homozygous

    2. 87 16 F 28 c.5001G.Cp.Q1667H Hmz ,1 5.3 12 - +

      Case: 87, F, 16 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: no family history of disease, Consanguinity: yes

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): <1, VWF:Ag (U/dl): 5.3, Bleeding Score: 12

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.5001G>C (p.Gln1667His), Exon 28

      Homozygous

    3. 64 2 M 28 c.3835G.A p.V1279I Hmz 5.2 ,1 6 - +c.3931C.T p.Q1311*

      Case: 64, M, 2 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: no family history of disease, Consanguinity: yes

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): 5.2, VWF:Ag (U/dl): <1, Bleeding Score: 6

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.3835G>A (p.Val1279Ile), Exon 28

      c.3931C>T (p.Gln1311*), Exon 28

      Homozygous

    4. 26 13 M 37 c.6418C.Tp.Q2140* Hmz ,1 ,1 8 + -

      Case: 26, M, 13 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: no, family history of disease

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): <1, VWF:Ag (U/dl): <1, Bleeding Score: 8

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.6418C>T (p.Gln2140*), Exon 37, Homozygous

    5. 31 16 F 8 c.903T.Ap.Y301* C. 6.5 4 6 - +22 c.2878C.T,c.2880G.Ap.R960* Htz

      Case: 31, F, 16 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: yes, no family history of disease

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): 6.5, VWF:Ag (U/dl): 4, Bleeding Score: 6

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.903T>A (p.Tyr301*), Exon 8

      c.2878C>T, c.2880G>A (p.Arg960*), Exon 22

      Compound Heterozygous

    6. 69 1.5 F 34 c.5793G.Cp.Q1931H Hmz ,1 ,1 2 - -

      Case: 69, F, 1.5 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: no family history of disease, Consanguinity: no

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): <1, VWF:Ag (U/dl): <1, Bleeding Score: 2

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.5793G>C (p.Gln1931His), Exon 34

      Homozygous

    7. 81 16 M 15 c.1863C.Ap.C621* Hmz 2 4.2 6 - -

      Case: 81, M, 16 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: no, no family history of disease

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): 2, VWF:Ag (U/dl): 4.2, Bleeding Score: 6

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.1863C>A (p.Cys621*), Exon 15, Homozygous

    8. 2 32 F 8 c.970C.T p.R324* Hmz 1 ,1 22 + -

      Case: 2, F, 32 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: no, family history of disease

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): 1, VWF:Ag (U/dl): 1, Bleeding Score: 22

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.970C>T (p.Arg324*), Exon 8, Homozygous

    9. 28 4 M 45 c.7558C.T p.Q2520* Hmz 3.2 3.2 7 + -

      Case: 28, M, 4 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: no, family history of disease

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): 3.2, VWF:Ag (U/dl): 3.2, Bleeding Score: 7

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.7558C>T (p.Gln2520* ), Exon 45, Homozygous

    10. 72 6 F 8 c.901_902insCTAp.E300_R302insSN Htz 2.5 4 4 - -

      Case: 72, F, 6 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: no family history of disease, Consanguinity: no

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): 2.5, VWF:Ag (U/dl): 4, Bleeding Score: 4

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.901_902insCTA (p.Glu300_Arg302insSerAsn), Exon 8

      Heterozygous

    11. 19 1.3 F 45 c.7603C.T p.R2535* Htz 3.6 1 4 + -

      Case: 19, F, 1.3 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: no, family history of disease

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): 3.6, VWF:Ag (U/dl): 1, Bleeding Score: 4

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.7603C>T (p.Arg2535*), Exon 45, Heterozygous

    1. 133115−−18Fc.3712C>T/c.3712C>Tp.Q1238X/p.Q1238X28/2816/16N/N

      Case: Patient 13, F, Hungarian

      DiseaseAssertion: VWD type 3

      FamilyInfo: compatible with recessive inheritance

      ParentalGenotype(s): n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeRext: Bleeding score: 18, VWF:Ag (IU dL−1): 1, VWF:CB (IU dL−1): 1, FVIII:C (IU dL−1): 5, VWF:RCo below detection limit (<10 IU dL−1), not detectable VWF on multimer gels, bleeding episode severity increased after the menarche

      CaseNOTHPOs: n/a

      CaseNOTHPOFreeText: no inhibitor detected, did not become refractory to factor replacement therapy

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.3712C>T (p.Gln1238X), Exon 28, Homozygous

      Intron 40 VNTR 16/16

      Note: multimer electrophoresis, Recombinant VWF antigen concentrations and Collagen binding activity (VWF:CB) measured by ELISA, direct sequencing of the 51 exons and the exon‐intron boundaries, Breakpoint analysis and breakpoint‐specific PCR

    2. 16*3115−−24Fc.3379+1G>A/c.3379+1G>ASplice/Splice25/2518/18PD/PD

      Case: Patient 16, F, Hungarian

      DiseaseAssertion: VWD type 3

      FamilyInfo: compatible with recessive inheritance

      ParentalGenotype(s): n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeRext: Bleeding score: 24, VWF:Ag (IU dL−1): 1, VWF:CB (IU dL−1): 1, VWF:RCo below detection limit (<10 IU dL−1), FVIII:C (IU dL−1): 5, not detectable VWF on multimer gels, bleeding episode severity increased after the menarche

      CaseNOTHPOs: n/a

      CaseNOTHPOFreeText: no inhibitor detected, did not become refractory to factor replacement therapy

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.3379+1G>A (Splice), Exon 25, Homozygous

      (p.Arg924Gln), Exon 21, Homozygous

      Intron 40 VNTR 18/18

      Note: multimer electrophoresis, Recombinant VWF antigen concentrations and Collagen binding activity (VWF:CB) measured by ELISA, direct sequencing of the 51 exons and the exon‐intron boundaries, Breakpoint analysis and breakpoint‐specific PCR

    3. 23342LMWM−21Mc.1730‐10C>A/c.5791C>TSplice/p.Q1931X15/3417/18N/N

      Case: Patient 23, M, Hungarian

      DiseaseAssertion: VWD type 3

      FamilyInfo: compatible with recessive inheritance

      ParentalGenotype(s): n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeRext: Bleeding score: 21, VWF:Ag (IU dL−1): 4, VWF:CB (IU dL−1): 2, VWF:RCo below detection limit (<10 IU dL−1), low‐molecular‐weight multimer on multimer gels

      CaseNOTHPOs: n/a

      CaseNOTHPOFreeText: no inhibitor detected, did not become refractory to factor replacement therapy

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.1730‐10C>A (Splice), Exon 15

      c.5791C>T (p.Gln1931X), Exon 34

      Intron 40 VNTR: 17/18

      Note: multimer electrophoresis, Recombinant VWF antigen concentrations and Collagen binding activity (VWF:CB) measured by ELISA, direct sequencing of the 51 exons and the exon‐intron boundaries, Breakpoint analysis and breakpoint‐specific PCR

    1. 58 Type2A(IIA)c.4880C>GN p.Pro1627Arg 28 A2 htz Missense O 19 4 21

      Case: IP #58 (also in row 22 table 6)

      DiseaseAssertion: type 2A (IIA) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 19; VWF:Ac [IU/dL] = 4; FVIII:C [IU/dL] = 21

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4880C>G p.Pro1627Arg

      HGVS:

      ClinVarID: not found

      CAID: CA383498774

      gnomAD: absent

    2. 4 c.4037A > C N p.Gln1346Pro 28 A1 htz Missense O 20 5 22 CSA 20

      Case: IP #4 in type 2M VWD sub-cohort (also in row 13 table 6)

      DiseaseAssertion: type 2M VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 20; VWF:Ac [IU/dL] = 5; FVIII:C [IU/dL] = 22; VWF:CB (IU/dL) = 20

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4037A>C p.Gln1346Pro

      HGVS:

      ClinVarID: not found

      CAID: CA383505695

      gnomAD: absent

    3. 22 Type2A (IIE)c.3518G>T p.Cys1173Phe 26 D3-TIL-3htz Missense na 23 16 37

      Case: IP #22

      DiseaseAssertion: type 2A (IIE) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 23; VWF:Ac [IU/dL] = 16; FVIII:C [IU/dL] = 37

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3518G>T p.Cys1173Phe

      HGVS:

      ClinVarID: not found

      CAID: CA383511188

      gnomAD: absent

    1. Case#: 21006, Age 40, Male, Blood Type O+ (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: The patient is one of 4 members of Family# 2103. Each patient has the p.Gly2083Asp variant. Some of the patients have a second variant.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding Score 8, VWF:Ag: 11, VWF:RCo: 10, FVIII:C:29, VWF:CB: 10.3

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations

      Gene: VWF

      Variant: NM_000552.4:c.6248G>A (p.Gly2083Asp)

      ClinVar: N/A

      CAID: CA383492072 CAID

      gnomAD: N/A

    2. Case#: 29002, Age 38, Female, Blood Type O+ (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: The patient is the only member of Family#2902.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding score 7, VWF:Ag: 22, VWF:RCo: 17, FVIII:C: 54, VWF:CB:17

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations.

      Gene: VWF

      Variant: NM_000552.4:c.3223-7_3236dup (p.Pro1079_Tyr1080insLeuGlnValAspProGluPro) and NM_000552.4(VWF):c.5277C>T (p.Asp1759=)

      ClinVar: 310061 ClinVar

      CAID: CA1139532066 and CA6402333 CAID1 CAID2

      gnomAD: MAF of 0.01423 (1837/129090 alleles) in the European (non-Finnish) population (CA6402333). gnomAD

    3. Case#: 30008, Age 24, Female, Blood Type A+ (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: The patient is one of two members of Family #3006. Both patients have the same variant.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding Score 12, VWF:Ag:18, VWF:RCo:19.3, FVIII:C: 35, VWF:CB: 21

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations.

      Gene: VWF

      Variant: NM_000552.4:c.6536C>T (p.Ser2179Phe)

      ClinVar: 100442 ClinVar

      CAID: CA228746 CAID

      gnomAD: N/A

    4. Case#: 35008, Age 64, Male, Blood Type A+ (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: The patient is the only member of Family# 3503.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: VWF:Ag: 5.3, VWF:RCo:5, FVIII:C: 10, VWF:CB: 4.9

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: Bleeding Score 2

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations.

      Gene: VWF

      Variant: NM_000552.4:c.1625C>G (p.Ala542Gly), NM_000552.4:c.5198T>C (p.Leu1733Pro), and NM_000552.4:c.6187C>T (p.Pro2063Ser)

      ClinVar: 381621 and 100436 ClinVar1 ClinVar2

      CAID: CA6403319, CA383496267, and CA202650 CAID1 CAID2 CAID3

      gnomAD: MAF of 0.001355 (48/ 35418 alleles) in the Latino population (CA6403319). gnomAD

      MAF of 0.04854 (1486/30616 alleles) in the South Asian population (CA202650). gnomAD

    5. Case#: 37005, Age 39, Female, Blood Type O+ (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: The patient is the only member of Family#3705.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding Score 9, VWF:Ag:26, VWF:RCo: 18, FVIII:C: 44, VWF:CB: 18

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations.

      Gene: VWF

      Variant: NM_000552.4:c.2878C>T (p.Arg960Trp)

      ClinVar: N/A

      CAID: CA6402916 CAID

      gnomAD: MAF of 0.0004900 (50/ 30612 alleles) in the South Asian population. gnomAD

    6. Case#: 30006, Age 70, Female, Blood Type A- (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: The patient is the only member of Family#3005.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding Score 17, VWF:Ag: 24, VWF:RCo: 29.4, FVIII:C:30, VWF:CB: 28

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations.

      Gene: VWF

      Variant: NM_000552.4:c.5336G>T(p.Arg1779Leu)

      ClinVar: N/A

      CAID: CA383495656 CAID

      gnomAD: MAF of 0.00002891 ( 1/ 34592 alleles) in the Latino population. gnomAD

    1. T136M/24240.0100c.2438dupGp.Gly813 fs18Heterozygous

      Case: T136, M, 24

      DiseaseAssertion: VWD type 3

      FamilyInfo: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: Bleeding Score: 24 (Kruskal–Wallis followed by Mann–Whitney U post-hoc testing Post-hoc testing ), VWF:Ag (IU/ml): 0.01, VWF:RCo (IU/ml): 0, FVIII:C (IU/ml): 0

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.2438dupG (p.Gly813 fs), Exon 18, Heterozygous

      Note: ELISA-based assay for detecting alloantibodies, genomic analysis via sequencing of leukocytes for the VWF gene including exons 1-52 and about 1.5 km of VWF promoter, PCR amplification for variant confirmation, SALSA-MLPAVWF assay evaluation for partial/total gene deletions when sequencing did not reveal pathogenic explanation

    2. T151M/27290.020.040.01c.3939G>A, c.5842 + 1 G>Cp.Arg1313*, -28/34Compound heterozygous

      Case: T151, M, 27

      DiseaseAssertion: VWD type 3

      FamilyInfo: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: Bleeding Score: 29 (Kruskal–Wallis followed by Mann–Whitney U post-hoc testing Post-hoc testing ), VWF:Ag (IU/ml): 0.02, VWF:RCo (IU/ml): 0.04, FVIII:C (IU/ml): 0.01

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.3939G>A (p.Arg1313*), Exon 28

      c.5842 + 1 G>C, Exon 34

      Compound heterozygous

      Note: ELISA-based assay for detecting alloantibodies, genomic analysis via sequencing of leukocytes for the VWF gene including exons 1-52 and about 1.5 km of VWF promoter, PCR amplification for variant confirmation, SALSA-MLPAVWF assay evaluation for partial/total gene deletions when sequencing did not reveal pathogenic explanation

    3. T103M/6560.020.040.02c.8418_8419insTCCCp.Ser2807 fs52Homozygous

      Case: T103, M, 65

      DiseaseAssertion: VWD type 3

      FamilyInfo: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: Bleeding Score: 6 (Kruskal–Wallis followed by Mann–Whitney U post-hoc testing Post-hoc testing ), VWF:Ag (IU/ml): 0.02, VWF:RCo (IU/ml): 0.04, FVIII:C (IU/ml): 0.02

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.8418_8419insTCCC (p.Ser2807 fs), Exon 52, Homozygous

      Note: ELISA-based assay for detecting alloantibodies, genomic analysis via sequencing of leukocytes for the VWF gene including exons 1-52 and about 1.5 km of VWF promoter, PCR amplification for variant confirmation, SALSA-MLPAVWF assay evaluation for partial/total gene deletions when sequencing did not reveal pathogenic explanation

    4. T166M/2010<0.10<0.100.06c.8418_8419insTCCCp.Ser2807 fs52Homozygous

      Case: T166, M, 20

      DiseaseAssertion: VWD type 3

      FamilyInfo: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: Bleeding Score: 10 (Kruskal–Wallis followed by Mann–Whitney U post-hoc testing Post-hoc testing ), VWF:Ag (IU/ml): <0.10, VWF:RCo (IU/ml): <0.10, FVIII:C (IU/ml): 0.06

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.8418_8419insTCCC (p.Ser2807 fs), Exon 52, Homozygous

      Note: ELISA-based assay for detecting alloantibodies, genomic analysis via sequencing of leukocytes for the VWF gene including exons 1-52 and about 1.5 km of VWF promoter, PCR amplification for variant confirmation, SALSA-MLPAVWF assay evaluation for partial/total gene deletions when sequencing did not reveal pathogenic explanation

    1. Case 10

      Case: Case 10, ages 2-17, Croatian

      DiseaseAssertion: VWD2A

      FamilyInfo:

      ParentalGenotypes(s):

      CasePresentingHPOs:

      CaseHPOFreeText:

      CaseNOTHPOs:

      CaseNOTHPOFreeText: bleeding score= 15, VWF:GPIbM (%)= <4, VWF:Ag (%)= 19.8, vWF:GPIbM/vWF:Ag ratio= 0.20, FVIII:C (%): 25, VWF: CBA (%)= 8.5

      CasePreviousTesting:

      Gene: VWF

      Variant: c.4517C>T, p.Ser1506Leu

      HGVS: NM_000552.5:c.4517C>T

      ClinVar: 100369

      gnomAD: not included

    2. Case 11

      Case: Case 11, ages 2-17, Croatian

      DiseaseAssertion: VWD2M

      FamilyInfo:

      ParentalGenotypes(s):

      CasePresentingHPOs:

      CaseHPOFreeText:

      CaseNOTHPOs:

      CaseNOTHPOFreeText: bleeding score= 9, VWF:GPIbM (%)= 13.4, VWF:Ag (%)= 59.0, vWF:GPIbM/vWF:Ag ratio= 0.23, FVIII:C (%): 89, VWF: CBA (%)= 20.2

      CasePreviousTesting:

      Gene: VWF

      Variant: c.4645G>A, p.Glu1549Lys

      HGVS: NM_000552.5:c.4645G>A

      ClinVar: 100379

      gnomAD: not included

    1. 38-yr-old Nepalese woman

      Case: 38 year old Napalese woman

      DiseaseAssertion: type 2N VWD

      FamilyInfo: mother and elder brother had bleeding manifestations since childhood.

      CasePresentingHPOs: HP:0005261, HP:0012233, HP:0000132, HP:0003645, HP:0003125

      CaseHPOFreeRext: diagnosed as hemophilia A with factor VIII level of 3.6%. normal CBC; bleeding time, 2 min; PT, 14.9 sec (11-14 sec); aPTT, 51.2 sec (24-38 sec); and factor VIII, 4.9% (50-150%)

      CaseNOTHPOFreeText: No abnormalities were found in the vWF antigen level (71.3%), ristocetin cofactor assay (130.4%), and multimer assay

      GenotypingMethod: direct DNA sequencing of the VWF gene

      Gene: VWF

      Variant: c.2446C>T (p.Arg816Trp)

      HGVS: NM_000552.5:c.2446C>T p.(Arg816Trp)

      ClinVarID: 295

      gnomAD: MAF of 0.0001667 (10/59984) in Admixed American population https://gnomad.broadinstitute.org/variant/12-6036488-G-A?dataset=gnomad_r4

    1. 23IranM/16<1—YesSevere5941G→TE1981X35HomozygousN.A.

      Case: 23, M, 16, Iranian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: Yes

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: VWF:Ag (U/dl): <1, Bleeding symptoms: Severe

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: Anti-VWF alloantibodies: no

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      5941G→T (Glu1981X), Exon 35, Homozygous

    2. 15IranF/18<1—YesMild788del24263del87HomozygousRsaI (+)

      Case: 15, F, 18, Iranian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: Yes

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: VWF:Ag (U/dl): <1, Bleeding symptoms: Mild

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: Anti-VWF alloantibodies: no

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      788del24 (263del8), Exon 7, Homozygous

    1. We were able to further investigate platelets and/or BOECs in one family with the Pro2808Leufs*24 variant. The pedigree and laboratory data is shown in Fig. 1. The IC, T105, is homozygous for Pro2808Leufs*24. One of her siblings heterozygous for the variant was also enrolled (T107).

      Case: IC-T105, Canadian, female

      DiseaseAssertion: VWD3

      FamilyInfo: Pedigree in Fig 1A, 4 homozygotes, 3 heterozygotes

      ParentalGenotype(s): not reported

      CasePresentingHPOs:

      CaseHPOFreeText: VWF:Ag = 0.02 IU/mL, VWF:RCo = 0.00 IU/mL, FVIII:C = 0.03, bleeding score = 18

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: sequencing of VWF gene

      PreviouslyPublished: PMID:23311757

      Gene: VWF

      Variant: c.8419_8422dup (p.Pro2808Lysfs*24) - Unregistered Variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

    1. Case: Case Report, female, 63yo

      DiseaseAssertion: VWD2B

      FamilyInfo: sister exhibited thrombocytopenia and mother had suffered from acute subdural hematoma in the context of chronic thrombocytopenia

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0002138, HP:0011854, HP:0001873, HP:0032044, HP:0030132

      (Subarachnoid hemorrhage, Hemoperitoneum, thrombocytopenia, Decreased vigilance, Absence of large von Willebrand factor multimers)

      CaseHPOFreeText: thrombocytopenia with pregnancy, platelet count fluctuated between 3 and 200 G/l, subarachnoid hemorrhage associated with a subdural hematoma after falling, hemostasis results were normal, meningeal hemorrhage, cephalalgia; FVIII:C: 1.63 IU/ml; VWF:RCo: 0.7 IU/ml; VWF:Ag: 1.8 IU/ml, ratio VWF:Rco/VWF/Ag: 0.39; Ristocetin-induced platelet agglutination could not be performed due to the severe thrombocytopenia

      CaseNOTHPOs: NA

      CaseNOTHPOFreeText: NA

      CasePreviousTesting: tests for autoimmune disease negative

      GenotypingMethod: NGS of exon 28 of VWF gene; variant confirmed via Sanger sequencing

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3946G>A (p.Val1316Met)

      HGVS: NM_000552.4(VWF):c.3946G>A (p.Val1316Met)

      ClinVarID: 290; https://www.ncbi.nlm.nih.gov/clinvar/variation/290/

      CAID:

      gnomAD: absent

    1. Higher and lower active circulating VWF levels: different facets of von Willebrand disease

      PMID: 26456374

      Gene: VWF

      HGNC: 12726

      Disease: von Willebrand disease type 2B

      MONDO: 0015629

      InheritancePattern: Autosomal Dominant

      Prevalence: Overall VWD prevalence is estimated to be as high as 1 in 100 in the general population, with 1 in 10,000 pursuing tertiary care referral ((PMID: 28847738).

      Penetrance: Fully penetrant / nearly fully penetrant for most pathogenic type 2 variants

    1. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)

      PMID: 16985174

      Gene: VWF

      HGNC: 12726

      Disease: von Willebrand disease type 2A

      MONDO: 0015628

      InheritancePattern: Autosomal Dominant

      Prevalence: Overall VWD prevalence is estimated to be as high as 1 in 100 in the general population, with 1 in 10,000 pursuing tertiary care referral ((PMID: 28847738).

      Penetrance: Fully penetrant / nearly fully penetrant for most pathogenic type 2 variants

    1. 5

      Case#: 5, male, 65yo

      DiseaseAssertion: VWD1

      FamilyInfo: grandson diagnosed with VWD

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000978, HP:0004846, HP:0012147, HP:0030129, HP:0030130 (Bruising susceptibility, Reduced quantity of VWF, Impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity)

      CaseHPOFreeText: Bleeding after oral surgery, ESRD awaiting renal transplantation, Type A blood, VWF:Ag (0·55–2 iu/ml) pre = 0·41, VWF:RCo (0·55–2 iu/ml) pre = 0·29, FVIII:C (0·55–2 iu/ml) pre = 0·31, FVIII:C/VWF:Ag ratio = 0·75, VWF:FVIII binding (>20%) = 12%, VWF:FVIII binding/VWF:Ag (>0·7) = 0·29, Uncomplicated kidney transplant with VWF concentrate replacement

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: N/A

      CasePreviousTesting: RFLP; confirmatory sequencing

      Gene: VWF

      Variant 1: NM_000552.4(VWF):c.2561G>A (p.Arg854Gln)

      ClinVar: 296; https://www.ncbi.nlm.nih.gov/clinvar/variation/296/

      gnomAD: MAF = 0.005692 (European Non-Finnish); https://gnomad.broadinstitute.org/variant/12-6143978-C-T

      Variant 2: N/A - stated to be a compound heterozygote for a 2N VWD and a presumed null mutation

    1. A cluster of mutations in the D3 domain of von Willebrand factor correlates with a distinct subgroup of von Willebrand disease: type 2A/IIE

      PMID: 20351307

      Gene: VWF

      HGNC: 12726

      Disease: von Willebrand disease type 2A

      MONDO: 0015628

      InheritancePattern: Autosomal Dominant

      Prevalence: Overall VWD prevalence is estimated to be as high as 1 in 100 in the general population, with 1 in 10,000 pursuing tertiary care referral ((PMID: 28847738).

      Penetrance: Fully penetrant / nearly fully penetrant for most pathogenic type 2 variants

    1. 31

      Case#: Melo-Nava_2007,31, F, 7 y.o. (report), Mestizo Mexican and French ancestry reported

      DiseaseAssertion: VWD type 3

      FamilyInfo: No consanguinity

      ParentalGenotype: NR

      CasePresentingHPOs:

      CaseHPOFreeText: low 42% VWF:Ag, low FVIII:C 40%, low RIPA 24%, moderate bleeding severity

      CaseNotHPOs: abnormal platelet count

      CaseNotHPOFreeText:

      CasePreviousTesting: not reported

      GenotypingMethod: PCR

      Gene: VWF

      Variant:

      HGVS: NM_000552.5(VWF):c.4883T>C (p.Ile1628Thr)

      ClinVarID: 284

      CAID:

      gnomAD: Not found

      MultipleGeneVariants:

    1. T3-4

      Case: T3-4, male, 16yo

      DiseaseAssertion: VWD3

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeText: Blood type: A+, bleeding score = 24, VWF:Ag (IU/mL) = 0.01; VWF:RCo (IU/mL) = 0.03; FVIII:C (IU/mL) = 0.01

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: qRT-PCR

      PreviouslyPublished:

      Gene: VWF

      Variant 1: c.1657dupT (p.Trp553Leufs*97)

      HGVS: n/a

      ClinVarID: n/a

      CAID: n/a

      gnomAD: n/a

      Variant 2: c.8419_8422dupTCCC (p.Pro2808Leufs*24)

      HGVS: n/a

      ClinVarID: n/a

      CAID: n/a

      gnomAD: n/a

    1. F2Proband P2K157E C1165RCompound heterozygous1.951.040.893.02.13.06

      Case: Proband 2 (P2)

      DiseaseAssertion: VWD III

      FamilyInfo:

      Father

      Lys157Glu impaired multimerization of von Willebrand factor; reduced oxidoreductase activity

      VWF are retained in the ER and fail to be transported to the Golgi

      APTT ratio (seconds): 0.94

      PT ratio (seconds): 1.02

      TT ratio (seconds): 0.98

      VWF: Ag (IU/dL): 87.2

      VWF:RCo (IU/dL): 80.3

      FVIII:C (IU/dL): 97.8

      BS: 1

      Mother

      Cys379Gly impaired multimerization of von Willebrand factor; reduced oxidoreductase activity

      VWF are retained in the ER and fail to be transported to the Golgi

      APTT ratio (seconds): 1.05

      PT ratio (seconds): 1.17

      TT ratio (seconds): 1.07

      VWF: Ag (IU/dL): 8.0

      VWF:RCo (IU/dL): 5.9

      FVIII:C (IU/dL): 13.1

      BS: 9

      ParentalGenotype: n/a

      Father: Lys157Glu, Heterozygous

      Mother: Cys379Gly, Heterozygous

      CasePresentingHPOs: n/a

      CaseHPOFreeText:

      Lys157Glu impaired multimerization; reduced oxidoreductase activity; undetectable von Willebrand factor (VWF) multimer

      VWF are retained in the ER and fail to be transported to the Golgi

      APTT ratio (seconds): 1.95

      PT ratio (seconds): 1.04

      TT ratio (seconds): 0.89

      VWF: Ag (IU/dL): 3.0

      VWF:RCo (IU/dL): 2.1

      FVIII:C (IU/dL): 3.0

      BS: 6

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      Lys157Glu

      Cys1165Arg

      Compound heterozygous

    1. 12-year-old girl

      Case#: 12 yr, female,

      DiseaseAssertion: HCM

      FamilyInfo: Father and younger brother also diagnosed, same mutation, brother asymptomatic,

      CasePresentingHPOs: Syncope, Left bundle branch block, third degree atrioventricular block, amaurosis fugax, vertigo, ventricular septal hypertrophy, mitral regurgitation (HP:0001279, HP:0011713, HP:0001709, HP:0100576, HP:0002321, HP:0005144, HP:0001653)

      CaseHPOFreeText: bilateral atrial enlargement to 44mm for left and 40 mm for right, interventricular septum thickened to 23mm, posterior left ventricle thickened to 10 mm, left ventricular ejection fraction of 51.8%, elevated plasma level B-type Natriuretic peptic 1165 pg/ml

      CaseNotHPOs: heart murmur (HP:0030148)

      CaseNotHPOFreeText: normal liver and spleen size, no edema, pericardial abnormality, no obstruction of left ventricular outflow tract, normal pasma amino acids and urine organic acids

      CasePreviousTesting: whole exome sequencing

      CaseGenotypingMethod: heart rate of 102/min; respiratory rate of 25/min; blood pressure of 127/74 mmHg; ECG; 175 QRS complex; Holter monitor; MRI; Etiologic investigations; Bioinformatic analysis based on Polymorphism Phenotyping v2, Sorting Intolerant From Tolerant;

      Variant: NM_000257.4(MYH7):c.2155C>T (p.Arg719Trp)

      ClinVar: 14104 https://www.ncbi.nlm.nih.gov/clinvar/variation/14104/

      CAID: N/A

      gnomAD: 0.00006481 https://gnomad.broadinstitute.org/variant/14-23895180-G-A

    1. Supplementary Data: Online Table 3

      Case:

      CasePreviousTesting: Full sarcomere testing (MYBPC3, TNNT2, TNNI3, MYL2, MYL3, TPM1, ACTC1), Additional testing (ABCC9, ACTN2, ANKRD1, BAG3, CALR3, CRYAB, CSRP3, DES, DMD, DSC2, DSG2, DSP, EMD, GLA, JPH2, JUP, LAMA4, LAMP2, LMNA, MYH6, MYPN, MYOZ1, MYOZ2, PKP2, PLN, PRKAG2, RBM20, RYR2, SCN5A, SGCD, TAZ, TCAP, TMEM43, TNNC1, TTN, VCL and LDB3)

      CaseGenotypingMethod: DNA isolated from peripheral blood, targeted enrichment, next-gen sequencing with panel of 46 genes

      Variant: NM_000257.3:c.2453T>A

      CAID: CA389048376, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA389048376

      gnomAD: n/a

    1. 57 unrelated Chinese patients with LVNC were recruited at Fuwai Hospital, Beijing, China. Detailed clinical evaluation was performed on the probands and available family members. DNA samples isolated from the peripheral blood of the index cases were screened for 10 sarcomeric genes, including MYH7, MYBPC3, MYL2, MYL3, MYH6, TNNC1, TNNT2, TNNI3, TPM1, and ACTC1

      Four MYH7 variants mentioned using reference transcript NM_000257.2

      c.464_466delTCT

      c.745C>G

      c.1106G>A

      c.2785G>A

    1. Family 1 reported by Postma et al. [2011]. The MYH7 mutation Tyr283Asp is segregating with LVNC, Ebstein anomaly and other congenital heart disease (CHD).

      CaseIII-3: female

      DiseaseAssertion: LVNC, Ebstin anomaly, congenital heart disease

      FamilyInfo: all mutation carriers have LVNC, with some having Ebstein anomaly and/or other CHD

      CasePresentingHPOs:

      CaseHPOFreeText:

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod:

      Variant: NM_000257.4:c.847T>G

      ClinVar: 66081

      CAID: CA016893

      gnomAD:

    1. Case 1

      Case1: 17 month onset

      DiseaseAssertion: Noncompaction of the ventricular myocardium

      FamilyInfo: No known family history of heart disease or sudden cardiac death, Has two sisters with the same MYH7 variant and similar phenotypes, See Fig 3 for pedigree

      CasePresentingHPOs: HP:0001279, HP:0001635, HP:0012818, HP:0031295, HP:0030718, HP:0005133, HP:0005180, HP:0001653, HP:0001723, HP:0002092, HP:0004890, HP:0030876, HP:0005168 (Syncope, Heart failure, Biventricular noncompaction cardiomyopathy, Left atrial enlargement, Right atrial enlargement, Right ventricular dilation, Tricuspid regurgitation, Mitral regurgitation, Restrictive cardiomyopathy, Pulmonary arterial hypertension, Elevated pulmonary artery pressure, Increased pulmonary capillary wedge pressure, Elevated right atrial pressure)

      HPOsFreeText: Both cardiac ventricles had a coarsely trabeculated and spongy appearance in posterior wall, lateral wall, apical segments, and right ventricle, LVEF at 51%, Short E-wave deceleration time at the transmitral level (85 msec) with a high E/A ratio (2.1), Ratio between the thickness of the noncompacted layer and the myocardial layer was 3.4:1, Underwent cardiac catheterization, Left ventricular systolic pressure and end-diastolic pressure were 95 mmHg and 37 mmHg respectively, Pulmonary vascular resistance was 4.0 Wood Unit m^2

      CaseNotHPOs: N/A

      NotHPOsFreeText: Normal left ventricle end-diastolic volume (110%), No other congenital heart disease

      CaseAddInfo: Died at age 2 yrs of advanced heart failure

      CasePreviousTesting: TruSight One sequencing panel was used for testing (Illumina)

      CaseGenotypingMethod: Blood samples were collected from the proband and his siblings and genomic DNA was extracted. Target enrichment was performed using the TruSight One sequencing panel (Illumina). Analysis was annotated and filtered, after which the MYH7 pathogenic variant was confirmed using PCR and Sanger sequencing.

      Variant: NM_000257.4(MYH7):c.5740G>A (p.Glu1914Lys)

      ClinVar: 43088 https://www.ncbi.nlm.nih.gov/clinvar/variation/43088/

      gnomAD: Not in gnomAD

      MultipleGeneVariants

      (1) PLEC Variant

      Variant: NM_000445.4:c.3005-8T>C

      CAID: CA187619061 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA187619061

      gnomAD: Not in gnomAD

    1. Supplementary Material 4

      Case M-28: Japanese

      DiseaseAssertion: idiopathic cardiomyopathy (HCM and DCM)

      CasePreviousTesting: Clinical evaluation, chest radiography, electrocardiography, echocardiography, cardiac catheterization, full testing (MYBPC3, TNNT2, TNNI3, MYL2, MYL3, TPM1, ACTC1)

      CaseGenotypingMethod: 8 sarcomeric genes amplified from genomic DNA via PCR then screened using bidirectional direct sequencing

      Variant: NM_000257.3(MYH7):c.2770G>A (p.Glu924Lys)

      ClinVar: 14092, https://www.ncbi.nlm.nih.gov/clinvar/variation/14092/

      gnomAD: n/a

    1. 45 yr old femaleproband

      Case#: 45 yr, female, diagnosed at 13 from heart murmur

      DiseaseAssertion: HCM

      FamilyInfo: sibling with HCM, family history of symptoms and same mutation

      CasePresentingHPOs: left ventricular hypertrophy (HP:0001712)

      CaseHPOFreeText: abnormal coaptation of the mitral valve, systolic anterior motion of the mitral valve,

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: N/A

      CaseGenotypingMethod: stem cell derivation and cardiomyocyte differentiation; hiPSC-cardiomyocyte shRNA silencing experiments; qPCR analysis of MYH7 alleles; ECG; Micropatterning; ASO silencing

      Variant: NM_000257.4(MYH7):c.1208G>A (p.Arg403Gln)

      ClinVar: 14087 https://www.ncbi.nlm.nih.gov/clinvar/variation/14087/

      CAID: N/A

      gnomAD: absent

    1. proband carrying double mutations (MYH7 R858C and TNNT2 R286H)

      CaseR858C: 44 year old (text states male, pedigree states female)

      DiseaseAssertion: HCM

      FamilyInfo: No family members manifested sudden death, lethal arrhythmia, LVOT obstruction, or severe heart failure.

      One family member also carried double mutations

      CaseHPOFreeText: greater LV hypertrophy than his family members who carried a single mutation

      CasePreviousTesting: systematic mutation screening of eight sarcomeric genes: (MYH7), (MYBPC3), (TNNT2), (TNNI3), (MYL2), (MYL3), (TPM1), and (ACTC), using direct DNA sequencing

      GenotypingMethod: Genomic DNA was isolated from the leukocytes of the peripheral blood. Polymerase chain reaction was used to amplify the exons and flanking intronic bases of the eight genes, including MYH7, MYBPC3, TNNT2, TNNI3, MYL2, and MYL3. When no mutation was found, analysis of the TPM1 and ACTC genes was performed

      MultipleGeneVariants:

      VariantMYH7: NM_000257.4:c.2572C>T

      ClinVar: 164324

      CAID: CA012656

      gnomAD: https://gnomad.broadinstitute.org/variant/14-23894085-G-A

      0.00006152 African

      VariantTNNT2: NM_001001430.3:c.857G>A

      ClinVar: 43677

      CAID: CA005304

      gnomAD: https://gnomad.broadinstitute.org/variant/1-201328348-C-T

      0.0008699 East Asian

    1. Patient #1: family history of a severe HCM patient carrying both thin (S215L in TPM1) and thick (D896N and E525K in MYH7) filament mutations

      CaseIII:2: 44 year old male, South Asian

      DiseaseAssertion: HCM, septal hypertrophic obstructive cardiomyopathy

      FamilyInfo: family history of two sudden cardiac deaths at ages 35 and 19, and three family members with septal hypertrophic obstructive cardiomyopathy

      CasePresentingHPOs: HP:0001279, HP:0002094, HP:0001962

      "Syncope, Dyspnea, Palpitations"

      CasePreviousTesting: screened sarcomeric thin filament protein gene, α-tropomyosin (TPM1), screening of seven other sarcomeric genes: MYH7, MYBPC3, TNNT2, TNNI3, MYL2, MYL3, and ACTC

      GenotypingMethod: sequences covering all the exons and exon–intron boundaries of TPM1 and seven other sarcomeric genes (MYH7, MYBPC3, TNNT2, TTN, TNNI3, MYL2, MYL3, and ACTC) were synthesized

      MultipleGeneVariants:

      VariantMYH7: NM_000257.4:c.2686G>A

      ClinVar: 132908

      CAID: CA012857

      gnomAD: not found

      VariantMYH7: NP_000248.2:p.Ile524Lys

      ClinVar: not found

      CAID: valid allele but not present in the registry

      gnomAD: not found

      VariantTPM1: NM_000366.6:c.644C>T

      ClinVar: 31883

      CAID: CA018243

      gnomAD: https://gnomad.broadinstitute.org/variant/15-63354418-C-T

      0.000008806 European (non-Finnish)

    1. Patient 2

      Case#: A 36-year-old Italian female

      DiseaseAssertion: Restrictive cardiomyopathy (RCM), associated with a homozygous TPM1 p.Asn279His variant.

      FamilyInfo: The patient’s parents are first cousins and confirmed heterozygotes for p.Asn279His (Fig 2).The patient’s 75-year-old father was diagnosed with HCM at 42 years of age. He reportedly has a history of heart failure but is currently asymptomatic. The patient’s 67-year-old mother had her first echocardiogram after the patient’s diagnosis.(Table I).

      ParentalTesting: Father and mother

      CasePresentingHPOs: HP:0100749, HP:0002875, HP:0002094, HP:0012764, HP:0003270, HP:0000131, HP:0001635

      CaseHPOFreeText: She was diagnosed with RCM and is being evaluated for heart transplantation. was referred for chest pain, lightheadedness, shortness of breath, significant fatigue, dyspnea on exertion, three-pillow orthopnea and abdominal bloating. Eighteen months previously, she had been diagnosed with an unspecified form of cardiomyopathy after developing volume overload while hospitalized for a right oophorectomy and uterine fibroid removal. Her symptoms were consistent with NYHA III–IV heart failure. She has continued to have significant heart failure symptoms that have been difficult to control with medical therapy. Freedom from arrhythmias, however, has been notable. She is currently being considered for orthotopic heart transplantation but her evaluation has been complicated by psychiatric issues.

      CaseNotHPOs: HP:0001279, HP:0010741

      CaseNotHPOFreeText: She denied syncope and lower extremity edema

      CasePreviousTesting: The patients father and mother were tested.

      Genotyping Method: Sarcomere gene sequencing

      FunctionalAnalysis: used computational analysis and evolutionary conservation to assess the variant of TPM1 p.Asn279His.

      Variant: NM_001018005.2:c.835A>C

      ClinVar: 43446

      CAID: CA018397

      gnomAD: NR

    1. The proband (II-9)

      CaseII-9: Male, 38 years diagnosis, China, Asian

      DiseaseAssertion: Hypertrophic cardiomyopathy

      FamilyInfo: Proband's father (I-1) and mother (I-2) had histories of mild episodes of dizziness, no other symptoms reported in the other family members

      CasePresentingHPOs: HP:0001279, HP:0001712, HP:0001639 (Syncope, Left ventricular hypertrophy, Hypertrophic cardiomyopathy)

      HPOsFreeText: Heart rate 62 bpm, PR interval 172 ms, QRS complex duration 88 ms, Diffuse repolarization changes with a late-onset inverted T-wave pattern, LVMI 109.55 g/m2, MLVWT 24 mm, Ejection Fraction 70%

      CaseNotHPOs: HP:0030148 (Heart murmur)

      NotHPOsFreeText: N/A

      CaseAddInfo: N/A

      CasePreviousTesting: See Table 1

      CaseGenotypingMethod: Genomic DNA was extracted from blood and amplified. It was then subjected to a sequencing panel with an Illumina sequencer based on the 96 genes related to cardiac function. All readings were aligned, with any variants confirmed by Sanger sequencing and filtered for pathogenicity.

      Variant: NM_000257.3:c.5151T>A (p.His1717Gln)

      CAID: CA389036862 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000257.3%3Ac.5151T%3EA

      gnomAD: Not in gnomAD

      Multiple Gene Variants:

      KCNQ1 Variant

      Variant: NM_000218.2:c.568C>T (p.Arg190Trp)

      ClinVar: 53070 https://www.ncbi.nlm.nih.gov/clinvar/variation/53070/

      gnomAD: Latino 2.896e-5, Overall 4.011e-6 https://gnomad.broadinstitute.org/variant/11-2591948-C-T

      MYLK2 Variant

      Variant: NM_033118.3:c.970A>G (p.Lys324Glu)

      ClinVar: CA408526793 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_033118.3%3Ac.970A%3EG

      gnomAD: African 6.453e-5, Overall 4.087e-6 https://gnomad.broadinstitute.org/variant/20-30412153-A-G

      TMEM70 Variant

      Variant: NM_017866.5:c.440T>C (p.Ile147Thr)

      ClinVar: 571761 https://www.ncbi.nlm.nih.gov/clinvar/variation/571761/

      gnomAD: East Asian 4.893e-4, Overall 3.579e-5 https://gnomad.broadinstitute.org/variant/8-74893513-T-C

    1. HCM006

      CaseHCM006: 15 yrs report, Vietnam, Asian

      DiseaseAssertion: Hypertrophic Cardiomyopathy

      FamilyInfo: Family history of sudden cardiac death

      CasePresentingHPOs: HP:0002875, HP:0001712, HP:0031295, HP:0011103, HP:0001653 (Exertional dyspnea, Left ventricular hypertrophy, Left atrial enlargement, Abnormality of the left ventricular outflow tract, Mitral regurgitation)

      HPOsFreeText: Maximal LV thickness 33 mm

      CaseNotHPOs: HP:0005110, HP:0001297, HP:0004756 (Atrial fibrillation, Stroke, Ventricular tachycardia)

      NotHPOsFreeText: N/A

      CaseAddInfo: N/A

      CasePreviousTesting: The gene panel included 10 sarcomeric genes (MYH7, MYBPC3, TNNT2, TNNI3, TPM1, MYL2, MYL3, ACTC1, TNNC1, MYH6), 9 genes encoding Z-disk components and Ca2+ homeostasis factors (LDB3, CSRP3, TCAP, VCL, ACTN2, MYOZ2, NEXN, JPH2, PLN), and 4 genes involved in HCM phenocopies (GLA, LAMP2, PRKAG2, TTR), All probands had left ventricular wall thickness >= 15 mm and no other diseases that can cause secondary hypertrophy

      CaseGenotypingMethod: The coding region, flanking sequences, and untranslated regions of each gene were enriched by LC-PCR, amplified, and sequenced on the Illumina MiSeq or MiniSeq platform. Identified variants were then filtered for pathogenicity and confirmed by Sanger sequencing.

      Variant: NM_000257.4(MYH7):c.2207T>C (p.Ile736Thr)

      ClinVar: 164342 https://www.ncbi.nlm.nih.gov/clinvar/variation/164342/

      gnomAD: Not in gnomAD

      Multiple Gene Variants

      (1) NEXN Variant

      Variant: NM_144573.3(NEXN):c.835C>T (p.Arg279Cys)

      ClinVar: 30994 https://www.ncbi.nlm.nih.gov/clinvar/variation/30994/

      gnomAD: 0.006303, http://gnomad.broadinstitute.org/variant/1-78392548-C-T

    1. 9

      Case9: Male, 46 years onset, 48 years diagnosis, Italy

      HPOsFreeText: See Group Phenotypes, ERT started at 48, GAA Activity at ~7.5 pmol/min/mg before ERT and ~11 after

      GroupGenotypingMethod: PCR Amplification and GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.525delT (p.Glu176Argfs*45)

      ClinVar: 4033 https://www.ncbi.nlm.nih.gov/clinvar/variation/4033/

      gnomAD: European (Non-Finnish) 1.880e-4, Overall 9.959e-5 http://gnomad.broadinstitute.org/variant/17-78078909-CT-C


      CaseAddInfo: Late Onset Pompe Disease

    2. 8

      Case8: Male, 16 years onset, 36 years diagnosis, Italy

      HPOsFreeText: See Group Phenotypes, ERT started at 36, GAA Activity at ~5 pmol/min/mg before ERT and ~13 after

      GroupGenotypingMethod: PCR Amplification and GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.525delT (p.Glu176Argfs*45)

      ClinVar: 4033 https://www.ncbi.nlm.nih.gov/clinvar/variation/4033/

      gnomAD: European (Non-Finnish) 1.880e-4, Overall 9.959e-5 http://gnomad.broadinstitute.org/variant/17-78078909-CT-C


      CaseAddInfo: Late Onset Pompe Disease

    3. 18

      Case18: Female, 50 years onset, 53 years diagnosis, Italy

      HPOsFreeText: See Group Phenotypes, ERT started at 56, GAA Activity at ~6 pmol/min/mg before ERT and ~9 after

      GroupGenotypingMethod: PCR Amplification and GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.1465G>A (p.Asp489Asn)

      ClinVar: 92465 https://www.ncbi.nlm.nih.gov/clinvar/variation/92465/

      gnomAD: European (Finnish) 4.621e-5, Overall 1.195e-5 http://gnomad.broadinstitute.org/variant/17-78084553-G-A


      CaseAddInfo: Late Onset Pompe Disease

    4. 3

      Case3: Male, 30 years onset, 66 years diagnosis, Italy

      HPOsFreeText: See Group Phenotypes, ERT started at 67, GAA Activity at ~8 pmol/min/mg before ERT and ~10 after

      GroupGenotypingMethod: PCR Amplification and GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.1927G>A (p.Gly643Arg)

      ClinVar: 4023 https://www.ncbi.nlm.nih.gov/clinvar/variation/4023/

      gnomAD: European (Non-Finnish) 3.667e-5, Overall 2.479e-5 http://gnomad.broadinstitute.org/variant/17-78086713-G-A


      CaseAddInfo: Late Onset Pompe Disease

    5. 1

      Case1: Male, 21 years onset, 31 years diagnosis, Italy

      HPOsFreeText: See Group Phenotypes, ERT started at 31, GAA Activity at ~7.5 pmol/min/mg before ERT and ~8 after

      GroupGenotypingMethod: PCR Amplification and GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.1927G>A (p.Gly643Arg)

      ClinVar: 4023 https://www.ncbi.nlm.nih.gov/clinvar/variation/4023/

      gnomAD: European (Non-Finnish) 3.667e-5, Overall 2.479e-5 http://gnomad.broadinstitute.org/variant/17-78086713-G-A


      CaseAddInfo: Late Onset Pompe Disease

    6. 13

      Case13: Male, 34 years onset, 45 years diagnosis, Italy

      HPOsFreeText: See Group Phenotypes, ERT started at 45, GAA Activity at ~10 pmol/min/mg before ERT and ~10.5 after

      GroupGenotypingMethod: PCR Amplification and GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.525delT (p.Glu176Argfs*45)

      ClinVar: 4033 https://www.ncbi.nlm.nih.gov/clinvar/variation/4033/

      gnomAD: European (Non-Finnish) 1.880e-4, Overall 9.959e-5 http://gnomad.broadinstitute.org/variant/17-78078909-CT-C


      CaseAddInfo: Late Onset Pompe Disease

    1. 7

      Patient7: 71yo

      CasePresentingHPOs: HP:0003325, HP:0002093, HP:0002315, HP:0004887, HP:0000822, HP:0003141, HP:0002870, HP:0020038

      HPOsFreeText: morning headache, GAA = 7%, BMI = 28.3, temporo-insular lacunes

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo: 18yr disease duration, variants in trans

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.4(GAA):c.-32-13T>G

      Clinvar: 4027, https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: 0.003582, http://exac.broadinstitute.org/variant/17-78078341-T-G

      Variant2: NM_000152.3:c.2530_2541del

      CAID: CA658795292, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA658795292

      gnomAD: n/a

    2. 5

      Patient5: 36yo

      CasePresentingHPOs: HP:0003325, HP:0002093, HP:0001513, HP:0002637

      HPOsFreeText: GAA = 4.6%, BMI = 35.1, normal CTA, right temporal pole ischaemia

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo: 4yr disease duration, variants in trans

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.4(GAA):c.-32-13T>G

      Clinvar: 4027, https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: 0.003582, http://exac.broadinstitute.org/variant/17-78078341-T-G

      Variant2: NM_000152.3:c.2530_2541del

      CAID: CA658795292, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA658795292

      gnomAD: n/a

    1. #4

      Case#: Subject number 4, female, 11 years (report)

      DiseaseAssertion: Pompe disease

      FamilyInfo: No known family member with PD

      CasePresentingHPOs: HP:0001638 (cardiomyopathy), HP:0002153 (hyperkalemia), HP:0001324 (muscle weakness)

      CaseHPOFreeText:

      CaseNotHPOs: HP:0003546 (Exercise intolerance), HP:0001252 (Hypotonia), HP:0003326 (Myalgia), HP:0002015 (dysphagia), HP:0002098 (respiratory distress), HP:0002094 (dyspnoea)

      CaseNotHPOFreeText: no biopsy, not asymptomatic

      CasePreviousTesting: "Enzymatic activity was detected by fluorometric techniques" "The GAA sequence was performed in all patients whose enzyme activity measured in DBS and lymphocytes was decreased."

      glucosidase activity: GAA activity was 0.16 mol/Lh in dried blood spots (normal range >0.75).

      Variant 1: NM_000152.5(GAA):c.-32-13T>C

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.1831G>A (p.Gly611Ser)

      Variant 2 ClinVarID: 935199

      Variant 2 CAid: CA401369553

      Zygosity: Compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    1. Case Report

      Case#: Patient (case report), male, 1 month old, ethnicity unknown

      DiseaseAssertion: Pompe disease

      FamilyInfo: No history of consanguinity in parents. The patient has a 15 months old sibling that is healthy.

      Family medical history was notable for tuberous sclerosis in the patient’s father’s first cousin.

      CasePresentingHPOs: HP:0200128, HP:0001639, HP:0002240

      (Biventricular hypertrophy, Hypertrophic cardiomyopathy, Hepatomegaly,

      CaseHPOFreeText: Echogenic mass within the left ventricle.

      Short-axis images revealed the possibility of an additional mass within the left ventricle adjacent to the papillary muscles

      Right axis deviation

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Normal results were noted for levels of plasma amino acids, lactate and pyruvate, total and free carnitine, and acylcarnitine compounds. Urine organic acid quantitation was normal.

      PR interval was normal

      CasePreviousTesting: The serum creatine kinase was elevated (478 U/L; normal 60–305 U/L).

      GAA activity in whole blood from a blood spot was 1.8 pmol/punch/hour (control 10–49 pmol/punch/hour)

      The GAA gene was sequenced.

      Variant 1: NM_000152.5(GAA):c.525del (p.Glu176fs)

      ClinVar: 4033

      CAID: CA220406

      gnomAD: N/A

      Variant 2: NM_000152.5(GAA):c.1927G>A (p.Gly643Arg)

      ClinVar: 4023

      CAID: CA116596

      gnomAD: Highest population MAF=0.00003667 (Euroean (non-Finnish))

      ParentalGenotype:N/A

      PreviouslyPublished:N/A

    1. 6

      Case#: Subject number 6(L)

      DiseaseAssertion: Late Onset Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: CK testing: 176 U/L (28-300 U/L is normal), AST: 61 U/L (24-72 U/L is normal), ALT: 39 U/L (17-63 U/L is normal), Hex4: 5.9 mmol/mol Creatinine (≤20 mmol/mol Creatinine is normal)

      glucosidase activity: GAA activity #1 was 1.32 micromole/L/h and GAA activity #2 (NBS) 0.88 in dried blood spots (>2.10 micromole/L/h is normal). 0.7 in confirmatory testing (>6.7 is normal).

      Variant 1: NM_000152.5(GAA):c.-32-13T>G

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.-32-13T>G

      Variant 2 ClinVarID: 4027

      Variant 2 CAid: CA116606

      Zygosity: homozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    2. 2

      Case#: Subject number 2(L)

      DiseaseAssertion: Late Onset Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: CK testing: 72 U/L (28-300 U/L is normal), AST: 21 U/L (24-72 U/L is normal), ALT: 23 U/L (17-63 U/L is normal), Hex4: 4.2 mmol/mol Creatinine (≤20 mmol/mol Creatinine is normal)

      glucosidase activity: GAA activity #1 was 1.86 micromole/L/h and GAA activity #2 (NBS) 1.44 in dried blood spots (>2.10 micromole/L/h is normal). 5.3 in confirmatory testing (>6.7 is normal).

      Variant 1: NM_000152.5(GAA):c.2238G>C

      Variant 1 ClinVarID: 265160

      Variant 1 CAid: CA8815665

      Variant 2: NM_000152.5(GAA):c.1552-3C>G

      Variant 2 ClinVarID: 419722

      Variant 2 CAid: CA8815383

      Zygosity: compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    3. 17

      Case#: Subject number 17(L)

      DiseaseAssertion: Late Onset Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: CK testing: 275 U/L (60-305 U/L is normal), AST: 150 U/L (22-71 U/L is normal), ALT: 42 U/L (7-50 U/L is normal), Hex4: 5.2 mmol/mol Creatinine (≤20 mmol/mol Creatinine is normal), BNP 44.5 pg/mL (0.0–100.0 pg/mL is normal)

      glucosidase activity: GAA activity #1 was 1.04 micromole/L/h and GAA activity #2 (NBS) 0.77 in dried blood spots (>2.10 micromole/L/h is normal). 1.80 in confirmatory testing (>3.88 is normal).

      Variant 1: NM_000152.5(GAA):c.-32-13T>G

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.-32-13T>G

      Variant 2 ClinVarID: 4027

      Variant 2 CAid: CA116606

      Zygosity: homozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    4. 29

      Case#: Subject number 29(L)

      DiseaseAssertion: Late Onset Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: N/A

      glucosidase activity: GAA activity #2 (NBS) 0.48 in dried blood spots (>2.10 micromole/L/h is normal).

      Variant 1: NM_000152.5(GAA):c.-32-13T>G

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.1547G>A

      Variant 2 ClinVarID: 983721

      Variant 2 CAid: CA401367155

      Zygosity: compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    1. c.743T > C(p.Leu248Pro)

      Case84

      HPOsFreeText: See Group Phenotypes


      CasePreviousTesting: Sanger sequencing

      CaseMethod1: Sanger sequencing and PCR Amplification

      CaseMethod2: Whole Exome Sequencing (WES)

      CaseGenotypingMethod: Patients were previously confirmed with Pompe disease by Sanger sequencing to capture the pathogenic variants. The process was repeated as part of the study taking care to amplify the coding regions and exon/intron boundaries to compare with the WES results afterwards.


      Variant1: NM_000152.4:c.743T>C (p.Leu248Pro)

      CAID: CA401363263 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.743T%3EC

      gnomAD: European (Non-Finnish) 1.551e-5, Overall 7.079e-6 http://gnomad.broadinstitute.org/variant/17-78081406-T-C


      Variant2: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      CaseAddInfo: Adult Late Onset Pompe Disease

    2. c.525delT(p.Glu176Argfs*45)

      Case46

      HPOsFreeText: See Group Phenotypes


      CasePreviousTesting: Sanger sequencing

      CaseMethod1: Sanger sequencing and PCR Amplification

      CaseMethod2: Whole Exome Sequencing (WES)

      CaseGenotypingMethod: Patients were previously confirmed with Pompe disease by Sanger sequencing to capture the pathogenic variants. The process was repeated as part of the study taking care to amplify the coding regions and exon/intron boundaries to compare with the WES results afterwards.


      Variant1: NM_000152.4:c.525delT (p.Glu176Argfs*45)

      ClinVar: 4033 https://www.ncbi.nlm.nih.gov/clinvar/variation/4033/

      gnomAD: European (Non-Finnish) 1.880e-4, Overall 9.959e-5 http://gnomad.broadinstitute.org/variant/17-78078909-CT-C


      Variant2: NM_000152.4:c.1655T>C (p.Leu552Pro)

      ClinVar: 279811 https://www.ncbi.nlm.nih.gov/clinvar/variation/279811/

      gnomAD: European (Non-Finnish) 7.053e-5, Overall 3.188e-5 http://gnomad.broadinstitute.org/variant/17-78085800-T-C


      CaseAddInfo: Infantile Onset Pompe Disease

    3. c.1754+1G > A

      Case8

      HPOsFreeText: See Group Phenotypes


      CasePreviousTesting: Sanger sequencing

      CaseMethod1: Sanger sequencing and PCR Amplification

      CaseMethod2: Whole Exome Sequencing (WES)

      CaseGenotypingMethod: Patients were previously confirmed with Pompe disease by Sanger sequencing to capture the pathogenic variants. The process was repeated as part of the study taking care to amplify the coding regions and exon/intron boundaries to compare with the WES results afterwards.


      Variant1: NM_000152.4:c.1754+1G>A

      ClinVar: 286458 https://www.ncbi.nlm.nih.gov/clinvar/variation/286458/

      gnomAD: Not in gnomAD


      Variant2: NM_000152.4:c.722_723delTT (p.Phe241Cysfs*88)

      CAID: CA658795235 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.722_723delTT

      gnomAD: Not in gnomAD


      CaseAddInfo: Infantile Onset Pompe Disease

    4. c.953T > C(p.Met318Thr)

      Case55

      HPOsFreeText: See Group Phenotypes


      CasePreviousTesting: Sanger sequencing

      CaseMethod1: Sanger sequencing and PCR Amplification

      CaseMethod2: Whole Exome Sequencing (WES)

      CaseGenotypingMethod: Patients were previously confirmed with Pompe disease by Sanger sequencing to capture the pathogenic variants. The process was repeated as part of the study taking care to amplify the coding regions and exon/intron boundaries to compare with the WES results afterwards.


      Variant1: NM_000152.4:c.953T>C (p.Met318Thr)

      ClinVar: 4021 https://www.ncbi.nlm.nih.gov/clinvar/variation/4021/

      gnomAD: African 8.608e-5, Overall 4.485e-5 http://gnomad.broadinstitute.org/variant/17-78081693-T-C


      Variant2: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      CaseAddInfo: Juvenile Late Onset Pompe Disease

    5. c.1293_1312del20(p.Gln433Aspfs*66)

      Case29

      HPOsFreeText: See Group Phenotypes


      CasePreviousTesting: Sanger sequencing

      CaseMethod1: Sanger sequencing and PCR Amplification

      CaseMethod2: Whole Exome Sequencing (WES)

      CaseGenotypingMethod: Patients were previously confirmed with Pompe disease by Sanger sequencing to capture the pathogenic variants. The process was repeated as part of the study taking care to amplify the coding regions and exon/intron boundaries to compare with the WES results afterwards.


      Variant1: NM_000152.4:c.1293_1312del (p.Gln433Aspfs*66)

      CAID: CA658795249 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.1293_1312del

      gnomAD: Not in gnomAD


      Variant2: NM_000152.4:c.1716C>G (p.His572Gln)

      CAID: CA401369055 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.1716C%3EG

      gnomAD: Not in gnomAD


      CaseAddInfo: Infantile Onset Pompe Disease

    1. CaseOPOPD-50: Male, Taiwan, Birth diagnosis

      HPOsFreeText: GAA (MS/MS) enzyme activity at 0.68 umol/hr/L

      GenotypingMethod: GAA Gene Sequencing and PCR Amplification


      Variant1: NM_000152.4:c.1634C>T (p.Pro545Leu)

      ClinVar: 4032 https://www.ncbi.nlm.nih.gov/clinvar/variation/4032/

      gnomAD: European (Finnish) 1.199e-4, Overall 1.774e-5 http://gnomad.broadinstitute.org/variant/17-78084822-C-T


      Variant2: NM_000152.4:c.1726G>A (p.Gly576Ser)

      ClinVar: 92467 https://www.ncbi.nlm.nih.gov/clinvar/variation/92467/

      gnomAD: East Asian 0.1427, Overall 0.01700 http://gnomad.broadinstitute.org/variant/17-78085871-G-A


      CaseAddInfo: One Pompe Mutation allele and One Pseudodeficency Mutation allele

    2. CaseOPOPD-40: Female, Taiwan, Birth diagnosis

      HPOsFreeText: GAA (MS/MS) enzyme activity at 0.99 umol/hr/L

      GenotypingMethod: GAA Gene Sequencing and PCR Amplification


      Variant1: NM_000152.4:c.872T>C (p.Leu291Pro)

      CAID: CA401363854 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.872T%3EC

      gnomAD: Not in gnomAD


      Variant2: NM_000152.4:c.1726G>A (p.Gly576Ser)

      ClinVar: 92467 https://www.ncbi.nlm.nih.gov/clinvar/variation/92467/

      gnomAD: East Asian 0.1427, Overall 0.01700 http://gnomad.broadinstitute.org/variant/17-78085871-G-A


      CaseAddInfo: One Pompe Mutation allele and One Pseudodeficency Mutation allele, 2 others have the same genotypes

    3. CaseLP-5: Male, Taiwan, Birth diagnosis

      HPOsFreeText: 4MU enzyme activity at 1.08, MS/MS ennzyme activity at 0.46

      GenotypingMethod: GAA Gene Sequencing and PCR Amplification


      Variant1: NM_000152.4:c.752C>T (p.Ser251Leu)

      ClinVar: 325781 https://www.ncbi.nlm.nih.gov/clinvar/variation/325781/

      gnomAD: East Asian 2.760e-3, Overall 3.540e-4 http://gnomad.broadinstitute.org/variant/17-78081415-C-T


      Variant2: NM_000152.4:c.761C>T (p.Ser254Leu)

      ClinVar: 325782 https://www.ncbi.nlm.nih.gov/clinvar/variation/325782/

      gnomAD: East Asian 2.759e-3, Overall 1.947e-4 http://gnomad.broadinstitute.org/variant/17-78081424-C-T


      Variant3: NM_000152.4:c.1726G>A (p.Gly576Ser)

      ClinVar: 92467 https://www.ncbi.nlm.nih.gov/clinvar/variation/92467/

      gnomAD: East Asian 0.1427, Overall 0.01700 http://gnomad.broadinstitute.org/variant/17-78085871-G-A


      Variant4: NM_000152.4:c.1935C>A (p.Asp645Glu)

      ClinVar: 4029 https://www.ncbi.nlm.nih.gov/clinvar/variation/4029/

      gnomAD: East Asian 1.729e-3, Overall 1.240e-4 http://gnomad.broadinstitute.org/variant/17-78086721-C-A


      CaseAddInfo: Suspected Late Onset Pompe Disease, Nomenclature indicates Variants 1 and 2 are in cis and Variants 3 and 4 are also in cis

    1. 7

      Case#: Patient 7, Gender N/A, Onset 3-4 months. Death around 1-2 years, Southeast Asian

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: P:0001639. HP:0005165, HP:0001270, HP:0002240

      (Dyspnea, Shortened PR interval, Motor delay, Hepatomegaly

      CaseHPOFreeText: BVH, Severe MR, SDD, CK 550u/l, EF

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting: Creatine Kinase enzyme 550u/l, Ejection fraction 30%, GAA enzyme activity in leukocytes was 0.05% of normal control value.

      PCR of all exons was performed and subsequently subjected to capillary Sanger sequencing in both directions

      Variant 1: NM_000152.5(GAA):c.1411_1414del (p.Glu471fs)

      ClinVar: 188874

      CAID: CA274067

      gnomAD: Highest population MAF = 0.0002513 in East Asian

      Variant 2: NM_000152.5(GAA):c.1933G>C (p.Asp645His)

      ClinVar: 189013

      CAID: CA274256

      gnomAD: Highest population MAF = 0.00005534 (East Asian)

      ParentalGenotype: Father was the carrier of variant 1 NM_000152.5(GAA):c.1411_1414del (p.Glu471fs)

      mother was carrier of variant 2 NM_000152.5(GAA):c.1933G>C (p.Asp645His)

      PreviouslyPublished: N/A

    2. 12

      Case#: Patient 12, Gender N/A, Onset at 3-4 months old, Southeast Asian

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001252, HP:0002090, HP:0002878, HP:0005165

      (Hypotonia, Pneumonia, Respiratory failure, Shortened PR interval)

      CaseHPOFreeText: Failed endotracheal extubation, BVH, mild sub-aortic obstruction, SDD, Ejection fraction 13%, creatine kinase levels 966 u/l

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: GAA enzyme activity in leukocytes was 0.10% of normal control value.

      PCR of all exons was performed and subsequently subjected to capillary Sanger sequencing in both directions

      Variant 1: c.1327-2A>G

      ClinVar: N/A

      CAID: CA401366177

      gnomAD: Highest population MAF = 0.0002297 (African)

      Variant 2: c.1437G>C (p.Lys479Asn)

      ClinVar: N/A

      CAID: CA401366671

      gnomAD: N/A

      ParentalGenotype: Mother was the carrier of variant 1 c.1327-2A>G

      Father was the carrier of variant 2 c.1437G>C (p.Lys479Asn)

      PreviouslyPublished:

    3. 1

      Case#: Patient 1, gender N/A, Age of onset was 7-8 months (died at 3 years of age), Southeast Asian

      DiseaseAssertion: Pompe Disease

      FamilyInfo:

      CasePresentingHPOs: HP:0001252, HP:0001270, HP:0001638, HP:0005165 (Muscular Hypotonia, Motor delay, Cardiomyopathy, Shortened PR interval)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: GAA activity in leukocytes was 0% of the normal control value.

      PCR of all exons was performed and subsequently subjected to capillary Sanger sequencing in both directions

      Variant1: NM_000152.5(GAA):c.876C>G (p.Tyr292Ter)

      ClinVar: 637958

      CAID: CA401363871

      gnomAD: N/A

      Variant2: NM_000152.5:c.1003G>A (p.Gly335Arg)

      ClinVar: 972790

      CAID: CA501005

      gnomAD: Highest population MAF = 0.00003266 (South Asian).

      ParentalGenotype: Patient inherited variant 1 (NM_000152.5(GAA):c.876C>G (p.Tyr292Ter) from father.

      Variant 2 (c.1003G>A (p.Gly335Arg)) was inherited from mother PreviouslyPublished:N/A

    4. 2

      Case#: Patient 2, Gender N/A, 1-2 months old at onset, Southeast Asian

      DiseaseAssertion: Pompe disease

      FamilyInfo: Patient has two previously deceased siblings with cardiomyopathy

      CasePresentingHPOs: HP:0002789, HP:0002240, HP:0005165, HP:0001639 (Tachypnea, Hepatomegaly, Shortened PR interval, Hypertrophic cardiomyopathy)

      CaseHPOFreeText: BVH, EF 30%

      CaseNotHPOs: N/A

      CaseNotHPOFreeText:N/A

      CasePreviousTesting: GAA activity in leukocytes was 0% of the normal control value

      PCR of all exons was performed and subsequently subjected to capillary Sanger sequencing in both directions

      Variant1: NM_000152.5(GAA):c.1935C>A (p.Asp645Glu)

      ClinVar: 4029

      CAID: CA116610

      gnomAD: Highes population MAF = 0.001729 (East Asian)

      Variant2: NM_000152.5(GAA):c.1933G>C (p.Asp645His)

      ClinVar:<br /> 189013

      CAID: CA274256

      gnomAD: Highest population MAF = 0.00005534 (East Asian)

      ParentalGenotype: Father was carrier of variant 1 c.1935C>A ( p.Asp645Glu

      Mother was carrier of the Variant 2 c.1933G>C (p.Asp645His

      PreviouslyPublished:

    1. 6

      Patient6: Female

      CasePresentingHPOs: HP:0002194, HP:0001522

      HPOsFreeText: ERT dosage = 20 mg/kg/2 w, CRIM negative

      CaseNotHPOs: HP:0004887

      NotHPOsFreeText: No reversal of HCM

      CaseAddInfo: Symptom onset at 1mo, diagnosis and ERT at 4mo, ERT lasted for 4mo, died at 11mo

      CasePMIDs: 22252923, 27629047

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant: NM_000152.3:c.1657C>T

      CAID: CA401368835, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.3%3Ac.1657C%3ET

      gnomAD: n/a

    2. 2

      Patient2: female

      CasePresentingHPOs: HP:0004887, HP:0002194, HP:0001263, HP:0002463, HP:0002870, HP:0011003, HP:0002289

      HPOsFreeText: ERT dosage = 20 mg/kg/2 w, use of BiPAP, could sit independently, HCM reversal, CRIM positive, BiPAP ventilation at night

      CaseNotHPOs: HP:0000407

      NotHPOsFreeText:

      CaseAddInfo: Symptom onset and diagnosis at 1d, ERT at 3w, required BiPAP at 57mo, ERT lasted for 77mo, currently 6.5yo

      CasePMIDs: 8401535

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant: NM_000152.4(GAA):c.1927G>A (p.Gly643Arg)

      ClinVar: 4023, https://www.ncbi.nlm.nih.gov/clinvar/variation/4023/

      gnomAD: 5.884e-05, http://exac.broadinstitute.org/variant/17-78086713-G-A

    1. 7

      Case#: Subject number 7, male, 62 years (diagnosis), 66 years (baseline visit), 67 years (ERT), 67 years (ventilation)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001324 (Muscle Weakness), HP:0002098 (respiratory distress)

      CaseHPOFreeText: mechanical ventilation at last visit

      CaseNotHPOs: HP:0003236 (Elevated circulating creatine kinase concentration), HP:0002870 (obstructive sleep apnea)

      CaseNotHPOFreeText: no mechanical ventilation at Baseline Visit

      CasePreviousTesting: "reduced enzymatic activity on fibroblasts, blood leukocytes or skeletal muscle and/or the presence of two known mutations in the GAA gene"

      PreviouslyPublished: N/A

    2. 2

      Case#: Subject number 2, female, 20 years (diagnosis), 48 years (baseline visit), 39 years (ERT), 34 years (ventilation)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001324 (Muscle Weakness), HP:0002098 (respiratory distress)

      CaseHPOFreeText: mechanical ventilation at Baseline Visit, mechanical ventilation at last visit

      CaseNotHPOs: HP:0003236 (Elevated circulating creatine kinase concentration), HP:0002870 (obstructive sleep apnea)

      CaseNotHPOFreeText:

      CasePreviousTesting: "reduced enzymatic activity on fibroblasts, blood leukocytes or skeletal muscle and/or the presence of two known mutations in the GAA gene"

      PreviouslyPublished: N/A

    3. 30

      Case#: Subject number 30, male, 12 years (baseline visit)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0003236 (Elevated circulating creatine kinase concentration)

      CaseHPOFreeText:

      CaseNotHPOs: HP:0002870 (obstructive sleep apnea), HP:0002098 (respiratory distress), HP:0001324 (Muscle Weakness)

      CaseNotHPOFreeText: no mechanical ventilation at Baseline Visit, no mechanical ventilation at last visit

      CasePreviousTesting: "reduced enzymatic activity on fibroblasts, blood leukocytes or skeletal muscle and/or the presence of two known mutations in the GAA gene"

      PreviouslyPublished: N/A

    4. 5

      Case#: Subject number 5, female, 20 years (diagnosis), 45 years (baseline visit), 42 years (ERT)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001324 (Muscle Weakness)

      CaseHPOFreeText:

      CaseNotHPOs: HP:0003236 (Elevated circulating creatine kinase concentration), HP:0002870 (obstructive sleep apnea), HP:0002098 (respiratory distress)

      CaseNotHPOFreeText: no mechanical ventilation at Baseline Visit, no mechanical ventilation at last visit

      CasePreviousTesting: "reduced enzymatic activity on fibroblasts, blood leukocytes or skeletal muscle and/or the presence of two known mutations in the GAA gene"

      PreviouslyPublished: N/A

    5. 4

      Case#: Subject number 4, female, 56 years (diagnosis), 63 years (baseline visit), 59 years (ERT)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001324 (Muscle Weakness)

      CaseHPOFreeText:

      CaseNotHPOs: HP:0003236 (Elevated circulating creatine kinase concentration), HP:0002870 (obstructive sleep apnea), HP:0002098 (respiratory distress)

      CaseNotHPOFreeText: no mechanical ventilation at Baseline Visit, no mechanical ventilation at last visit

      CasePreviousTesting: "reduced enzymatic activity on fibroblasts, blood leukocytes or skeletal muscle and/or the presence of two known mutations in the GAA gene"

      PreviouslyPublished: N/A

    1. Patient 1

      Case#: Patient 1, female, symptoms began at birth, began ERT at 2.4mo

      DiseaseAssertion: Pompe Disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0002789, HP:0001639, HP:0010628, HP:0000010 (tachypnea, hypertrophic cardiomyopathy, facial nerve palsy, persistent urinary tract infections)

      CaseHPOFreeText: diagnosed IOPD, frequent airway infections, motor function significant decline

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: <1% normal GAA expression in fibroblast; after ERT treatment had 100% enzyme activity in cell lysates; unclear how patient was diagnosed

      Variant 1: NM_000152.5:c.2481+102_2646+31del538

      Variant 1 ClinVarID: 657307

      Variant 1 CAid: CA65879529

      Variant 2: NM_000152.5:c.2481+102_2646+31del538

      Variant 2 ClinVarID: 657307

      Variant 2 CAid: CA658795291

      ParentalGenotype: Not provided

    1. LOPD-9

      CaseLOPD-9: 3 weeks diagnosis

      HPOsFreeText: GAA activity 4.1 (nmol · h−1 · mg−1), Mean percentage of normal 5.8%

      GenotypingMethod: Newborn Screening Panels


      Variant1: NM_000152.4:c.266G>A (p.Arg89His)

      ClinVar: 283219 https://www.ncbi.nlm.nih.gov/clinvar/variation/283219/

      gnomAD: Ashkenazi Jewish 1.168e-3, Overall 1.395e-4 http://gnomad.broadinstitute.org/variant/17-78078651-G-A


      Chromosomal code not provided

      Variant2: NP_000143.2:p.E176fsX45

      ClinVar: N/A

      gnomAD: N/A


      CaseAddInfo: Late Onset Pompe Disease

    2. PD/Pathogenic-1

      CasePD/Pathogenic-1: 5 weeks diagnosis

      HPOsFreeText: GAA activity 16.6 (nmol · h−1 · mg−1), Mean percentage of normal 23.2%

      GenotypingMethod: Newborn Screening Panels


      Variant1: NM_000152.4:c.1726G>A (p.Gly576Ser)

      ClinVar: 92467 https://www.ncbi.nlm.nih.gov/clinvar/variation/92467/

      gnomAD: East Asian 0.1427, Overall 0.01700 http://gnomad.broadinstitute.org/variant/17-78085871-G-A


      Variant2: NM_000152.4:c.2065G>A (p.Glu689Lys)

      ClinVar: 4030 https://www.ncbi.nlm.nih.gov/clinvar/variation/4030/

      gnomAD: East Asian 0.2355, Overall 0.05524 http://gnomad.broadinstitute.org/variant/17-78087041-G-A


      Variant3: NM_000152.4:c.752C>T (p.Ser251Leu)

      ClinVar: 325781 https://www.ncbi.nlm.nih.gov/clinvar/variation/325781/

      gnomAD: East Asian 2.760e-3, Overall 3.540e-4 http://gnomad.broadinstitute.org/variant/17-78081415-C-T


      Variant4: NM_000152.4:c.761C>T (p.Ser254Leu)

      ClinVar: 325782 https://www.ncbi.nlm.nih.gov/clinvar/variation/325782/

      gnomAD: East Asian 2.759e-3, Overall 1.947e-4 http://gnomad.broadinstitute.org/variant/17-78081424-C-T


      CaseAddInfo: Patient has one pseudodeficency allele and one pathogenic allele, Nomenclature claims Variant 1 and 2 are in cis, Nomenclature claims Variant 3 and 4 are in cis

    1. 14

      Case#: Subject number 14, male, 63 years (report), 47 years (onset), 58 years (diagnosis)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0000365 (hearing loss), HP:0000360 (tinnitus)

      CaseHPOFreeText: On BiPAP, ambulatory, assistive device (cane)

      CaseNotHPOs: HP:0000821, HP:0002650, HP:0002617, HP:0000939, HP:0009830, HP:0100647, HP:0010788, HP:0001638 (hypothyroidism, scoliosis, aneurysm, osteoporosis, peripheral neuropathy, Graves disease, Testicular cancer, cardiomyopathy)

      CaseNotHPOFreeText: no infusion reaction, no tracheostomy

      CasePreviousTesting: “documented deficiency of acid alpha-glucosidase enzyme activity”; on enzyme replacement therapy

      Variant 1: NM_000152.5(GAA):c.-32-13T>G (p.Tyr766Ser)

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.1445C>G

      Variant 2 ClinVarID: N/A

      Variant 2 CAid: CA401366794

      Zygosity: Compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    2. 1

      Case#: Subject number 1, male, 22 years (report), 9 years (onset), 11 years (diagnosis)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0002650, HP:0001638 (Scoliosis, cardiomyopathy)

      CaseHPOFreeText: on BiPap, ambulatory

      CaseNotHPOs: HP:0002617, HP:0000365, HP:0000360, HP:0000939, HP:0009830, HP:0100647, HP:0010788, HP:0000821 (aneurysm, hearing loss, tinnitus, osteoporosis, peripheral neuropathy, Graves disease, Testicular cancer, hypothyroidism)

      CaseNotHPOFreeText: No infusion reaction, no tracheostomy

      CasePreviousTesting: “documented deficiency of acid alpha-glucosidase enzyme activity”; on enzyme replacement therapy

      Variant 1: NM_000152.5(GAA):c.1655T>C (p.Leu552Pro)

      Variant 1 ClinVarID:279811

      Variant 1 CAid:CA8815429

      Variant 1 gnomAD MAF: 0.00007053; 8/113426 (European non-Finnish)[https://gnomad.broadinstitute.org/variant/17-78085800-T-C?dataset=gnomad_r2_1]

      Variant 2: NM_000152.5(GAA):c.2238G>C (p.Trp746Cys)

      Variant 2 ClinVarID:265160

      Variant 2 CAid:CA9301331

      Variant 2 gnomAD MAF: 0.0005673; 73/128684 (European non-Finnish)[https://gnomad.broadinstitute.org/variant/17-78090815-G-C?dataset=gnomad_r2_1]

      Zygosity: Compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    1. Detailed characteristics of these patients

      Patient2: female, 16yo, juvenile onset

      CasePresentingHPOs:

      HPOsFreeText: LOPD, BMI = 17.7;20.3;20.3, WGMS = 2;2;2

      CaseNotHPOs: HP:0002355

      NotHPOsFreeText: did not require respiratory support

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1:NM_000152.4(GAA):c.-32-13T>G

      Clinvar: 4027, https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: 0.003582, http://exac.broadinstitute.org/variant/17-78078341-T-G

      Variant2: NM_000152.4(GAA):c.307T>G (p.Cys103Gly)

      ClinVar: 92483, https://www.ncbi.nlm.nih.gov/clinvar/variation/92483/

      gnomAD: n/a

    1. 22/F

      Patient22: Female

      CasePresentingHPOs: HP:0004887, HP:0011471, HP:0001371

      HPOsFreeText: CRIM positive, tracheostomy, able to sit independently, heart normalization

      CaseNotHPOs: HP:0002546, HP:0000365

      NotHPOsFreeText: infusion associated reaction

      CaseAddInfo: homozygous variants in trans, symptom onset and diagnosis at 4yo, ERT at 5yo

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant: NM_000152.4(GAA):c.1927G>A (p.Gly643Arg)

      ClinVar: 4023, https://www.ncbi.nlm.nih.gov/clinvar/variation/4023/

      gnomAD: 0.00002479, http://gnomad.broadinstitute.org/variant/17-78086713-G-A

    2. 21/F

      Patient 21: Female

      CasePresentingHPOs: HP:0004887, HP:0011471, HP:0002546, HP:0000365, HP:0001371, HP:0100845

      HPOsFreeText: CRIM positive, infusion associated reaction, tracheostomy, able to sit independently, heart normalization

      CaseNotHPOs:

      CaseAddInfo: variants in trans, symptom onset at birth, diagnosis at 19 days, ERT at 1yo

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.3:c.930_932del

      CAID: CA913184760, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA913184760

      Variant2: NM_000152.4(GAA):c.1927G>A (p.Gly643Arg)

      ClinVar: 4023, https://www.ncbi.nlm.nih.gov/clinvar/variation/4023/

      gnomAD: 0.00002479, http://gnomad.broadinstitute.org/variant/17-78086713-G-A

    3. 15/F

      Patient15: female

      CasePresentingHPOs: HP:0001371

      HPOsFreeText: Anti-rh GGA antibodies maximum titer = ≤ 1:400, heart normalization, moderate periventricular white matter abnormalities (hypomyelination)

      CaseNotHPOs: HP:0004887, HP:0025156, HP:0002355, HP:0002546, HP:0000365

      NotHPOsFreeText: infusion associated reaction

      CaseAddInfo: variants in trans, symptom onset at birth, diagnosis at 5 days, ERT at 8 days

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.3:c.955+1G>A

      CAID: CA401364293, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.3%3Ac.955%2B1G%3EA

      gnomAD: n/a

      Variant2: NM_000152.4(GAA):c.1438-2A>G

      ClinVar: 526521, https://www.ncbi.nlm.nih.gov/clinvar/variation/526521/

      gnomAD: n/a

    1. 2

      Case# Patient 2, male

      CasePresentingHPOs: HP:0003236, HP:0003325

      CaseAddInfo: 66 at onset, 72 at diagnosis

      VariantAllele1: NM_000152.4(GAA):c.-32-13T>G

      ClinVar: 4027, https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: 0.003582, http://exac.broadinstitute.org/variant/17-78078341-T-G

      VariantAllele2: NM_000152.4(GAA):c.525delT (p.Glu176Argfs)

      ClinVar: 4033

      gnomAD: 7.041e-05, http://exac.broadinstitute.org/variant/17-78078909-CT-C

    2. Clinical and laboratory features of the 17 newly diagnosed patients with LOPD

      GroupPresentingHPOs: HP:0003325, HP:0003457, HP:0012548, HP:0004887, HP:0010535, HP:0001712, HP:0031296

      HPOsFreeText: hyperCKaemia+LGMW, BMI, mean (SD) 25.2±5.8, Serum CK, mean (SD) 600±302, vacuolar myopathy, Muscle GAA %, mean (SD) 9.4±3.8, myogenic EMG, abnormal MRI, %Predicted FVC, mean (SD) 73±11, 6MWT, mean (SD) 452±9, vacuolisation of myofibers with variable glycogen storage, AP staining low in 6 individuals, medium in five, and high in 2 individuals. Low residual GAA activity in muscles,

      GroupNotHPOs:

      NotHPOsFreeText:

      NumberMales: 8

      NumberFemales: 9

      CountryOrigin: n/a

      AgeRange: mean (SD) 40±14.36

      TotalNumber: 14

      GroupAddInfo: mean age at disease onset was 40±14.3 years, median age at disease diagnosis was 47±14 years. 14 of the individuals underwent enzyme replacement therapy. Blood CK levels increased in all but one individual.

      GroupGenotypingMethod: GAA gene sequencing

      Variant 1: NM_000152.4(GAA):c.-32-13T>G

      ClinVar: 4027, https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: 0.003582, http://exac.broadinstitute.org/variant/17-78078341-T-G

      Variant 2: p.P522A, NM_000152.4(GAA):c.1564C>G (p.Pro522Ala)

      ClinVar: 371277, https://www.ncbi.nlm.nih.gov/clinvar/variation/371277/

      gnomAD: n/a

    3. 4

      Case# Patient 4, female

      CasePresentingHPOs: HP:0003236, HP:0003325

      CaseAddInfo: 31yo at onset, 40yo at diagnosis

      VariantAllele1: NM_000152.4(GAA):c.-32-13T>G

      ClinVar: 4027, https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: 0.003582, http://exac.broadinstitute.org/variant/17-78078341-T-G

      VariantAllele2: NM_000152.4(GAA):c.1564C>G (p.Pro522Ala)

      ClinVar: 371277, https://www.ncbi.nlm.nih.gov/clinvar/variation/371277/

      gnomAD: n/a

    1. 36

      Patient36: Male, 3 year onset

      CasePresentingHPOs: HP:0001324, HP:0002098, HP:0003236 (Muscle weakness, Respiratory distress, Increased serum CK)

      HPOsFreeText: GAA activity 5.7% from leukocyte, Wheelchair needed, Respiratory Assistance needed

      CaseNotHPOs: HP:0001640, HP:0002240 (Cardiomegaly, Hepatomegaly)

      NotHPOsFreeText: N/A

      CaseAddInfo: LOPD550825

    1. 17

      Case#: P 17, Female, 5.5 mo nths old when started ERT (62.8 months old when last reported), German

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: P:0001639 , HP:0001252 , HP:0003701, HP:0006532

      (Hypertrophic cardiomyopathy, Muscular hypotonia, Proximal muscle weakness, Recurrent Pneumonia)

      CaseHPOFreeText: Recurrent pneumonia was a complication during ERT

      Best and last motor status was walking

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: Did not required tube feeding nor ventilation

      CasePreviousTesting: CRIM status was unknown

      Antibody titer 1:800

      Variant: NM_000152.5(GAA):c.1978C>T (p.Arg660Cys)

      ClinVar: 558604

      CAID: CA8815561

      gnomAD: MAF=0.00005554 in East Asian

      ParentalGenotype: Both the paternal and maternal allele carried the NM_000152.5(GAA):c.1978C>T (p.Arg660Cys) Variant

      PreviouslyPublished: N/A

    2. 11

      Case#: P 11, Male, 2.6 months old when started ERT (Died at 14.1 months old), German

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001639 , HP:0001252 , HP:0003701, HP:0011951

      (Hypertrophic cardiomyopathy, Muscular hypotonia, Proximal muscle weakness, Aspiration pneumonia )

      CaseHPOFreeText: AR IV

      Patient required ventilation and tube feeding

      No motor activity reported

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: CRIM status is negative

      Antibody titer is 1:51.200

      Variant: NM_000152.5(GAA):c.1548G>A (p.Trp516Ter)

      ClinVar: 189025

      CAID: CA274281

      gnomAD: MAF=0.00001552 in European non-Finnish

      ParentalGenotype: Both the paternal and maternal allele carry the variant c.1548G>A (p.Trp516Ter)

      PreviouslyPublished: N/A

    3. 3

      Case#: P 3, Male, 4.9 months when started ERT (122.1 months old at publication date), Ethnicity unknown

      DiseaseAssertion: Pompe disease

      FamilyInfo: Table 1 includes parental genotype

      CasePresentingHPOs: HP:0001639 , HP:0001252 , HP:0003701, HP:0002028

      (Hypertrophic cardiomyopathy, Muscular hypotonia, Proximal muscle weakness, Chronic diarrhea )

      CaseHPOFreeText: Chronic diarrhea was a complication during ERT

      Patient best and last/current status was being able to sit

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: Patient did not required tube feeding

      Patient did not required ventilation

      CasePreviousTesting: CRIM status is positive in patient

      Antibody titer is 1:200

      Variant 1: c.IVS17 + 102_IVS18 + 3

      ClinVar: N/A

      CAID: 657307

      gnomAD: N/A

      Variant 2: c.1465G>T (p.Asp489Tyr)

      ClinVar: N/A

      CAID: CA401366871

      gnomAD: N/A

      ParentalGenotype: The maternal allele of the patient carried the c.IVS17 + 102_IVS18 + 31 Variant

      The paternal allele of the patient carried the c.1465G>T (p.Glu489Ter) Variant

      PreviouslyPublished: N/A

    4. 7

      Case#: P 7, Female, 2.3 months old when started ERT (90.6 months old at publication date), ethnicity unknown

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001639 , HP:0001252 , HP:0003701, HP:0031846, HP:0030242

      (Hypertrophic cardiomyopathy, Muscular hypotonia, Proximal muscle weakness, Femur fracture, Portal vein thrombosis)

      CaseHPOFreeText: Femur fracture and Port thrombosis were complications during ERT

      Best motor status was walking, last motor status was sitting

      Patient required ventilation

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: Did not required tube feeding

      CasePreviousTesting: CRIM status is positive

      Antibody titer is 1:800

      Variant: NM_000152.5(GAA):c.1933G>A (p.Asp645Asn)

      ClinVar: 188728

      CAID: CA273892

      gnomAD: Highest population MAF= 0.00006599 in Africans

      ParentalGenotype: Both the paternal and maternal allele carried the variant c.1933G>A (p.Asp645Asn)

      PreviouslyPublished: N/A

    1. 10

      Family 10 - Patient 10

      FamilyPresentingHPOs: HP:0007340, HP:0003701, HP:0003327, HP:0040081, HP:0002111

      HPOsFreeText: muscle pathology with vacuolar myopathy

      FamilyNotHPOs: HP:0010628, HP:0002015, HP:0003691, HP:0003306, HP:0002650

      Ethnicity: Iranian

      ProbandLabel:

      FamilyAddInfo: onset at 38yo, diagnosis at 50yo, MRC sum score = 73, patient required use of NIV

      FamilyPreviousTesting: Respiratory Evaluation: FVC = 65%, CK = 551 U/L, muscle pathology examined, DBS enzyme activity (with inhibition) = 0.12 μmol/L/h

      FamilyGenotypingMethod: GAA analyzed with Sanger Sequencing for entire coding region and conserved exon-intron splice junctions, PCR performed for deletion screening

      VariantAllele1: NM_000152.4(GAA):c.-32-13T>G

      Clinvar: 4027, https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: 0.003582, http://exac.broadinstitute.org/variant/17-78078341-T-G

      VariantAllele2: NM_000152.3:c.2596delG

      CAID: CA891834514, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA891834514

      gnomAD: n/a

    2. 4a

      Family 4 - Patients 4a and 4b

      FamilyPresentingHPOs: HP:0007340, HP:0003701, HP:0000467, HP:0003327, HP:0010628, HP:0002015, HP:0003306, HP:0002111, HP:0011807, HP:0003554, HP:0002111, HP:0100298, HP:0040081

      HPOsFreeText: myopathic muscle unit action potentials, 4b muscular pathology with mild atrophy of type 1 and 2 fibers with many moth‐eaten fibers, no vacuoles, no glycogen excess

      FamilyNotHPOs: HP:0003691, HP:0002650

      NotHPOsFreeText:

      Ethnicity: Iranian

      ProbandLabel: 4a, female, 7yo at onset, 30yo at diagnosis

      FamilyAddInfo: 4b (male) dx at 23yo, 4a MRC sum score = 84, 4b MRC sum score = 86, both patients required use of NIV

      FamilyPreviousTesting: Respiratory Evaluation: 4a FVC = 29%, 4b FVC = 66%, 4a CK = 760 U/L, 4b CK = 3,257 U/L, muscle pathology (examined only in 4b), DBS enzyme activity (with inhibition) for 4a = 0.1 μmol/L/h, for 4b = 0.13 μmol/L/h, NCS, EMG

      FamilyGenotypingMethod: GAA analyzed with Sanger Sequencing for entire coding region and conserved exon-intron splice junctions, PCR performed for deletion screening

      VariantAllele1: NM_000152.4(GAA):c.-32-13T>G

      Clinvar: 4027, https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: 0.003582, http://exac.broadinstitute.org/variant/17-78078341-T-G

      VariantAllele2: NM_000152.3:c.1650delG

      Clinvar: n/a

      CAID: CA627699787, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA627699787

      gnomAD: n/a

    1. 1

      Case#: Patient 1, Gender N/A, age N/A, ethnicity unknown

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001638, HP:0003756

      (Cardiomyopathy, Skeletal myopathy)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: Sequence analysis of the GAA gene was performed in a CLIA and CAP certified laboratory.

      Cross Reactive Immune reaction was indeterminate in peripheral blood mononuclear cells (PBMCs)

      Cross Reactive Immune reaction was negative in Dried blood spots.

      Variant 1: c.437delT (p.Met146ArgfsX7)

      ClinVar: N/A

      CAID: N/A

      gnomAD: N/A

      Variant 2: NM_000152.5(GAA):c.2237G>A (p.Trp746Ter)

      ClinVar: 280063

      CAID: CA8815664

      gnomAD: Two variants with same consequence (protein) were identified.

      Highest population MAF = 0.00004011 (African)

      Highest population MAF = 0.000008834 (European non-Finnish)

      ParentalGenotype: N/A

      Previously published: N/A

    1. For GAA (Pompe disease) screening,

      CaseP5-GAA: female, ethnicity = South Asian, country origin = Nepal

      CasePresentingHPOs:

      HPOsFreeText: enzyme activity = 2.27

      CaseNotHPOs: HP:0010899, HP:0010916, HP:0003236

      CaseAddInfo: known pseudodeficiency allele (c.1726G>A)

      CasePreviousTesting: initial and confirmatory DBS, biochemical tests

      CaseGenotypingMethod: mutation analyses

      Variant: NM_000152.4(GAA):c.-32-13T>G

      Clinvar: 4027, https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: n/a

    1. 3

      Case3: Female, 0.8 yr onset, 1.1 yr diagnosis, 8.9 yr report

      CasePresentingHPOs: HP:0005165 (Shortened PR interval)

      HPOsFreeText: FVC z-score sitting 0.21 (102% pred), FVC z-score supine 0.1 (101% pred), 358 CK U/l, 13.3 GAA activity (nmol/h/mg)^h from cultured fibroblasts, ECG showed delta wave suggestive of Wolff-Parkinson-White syndrome

      NotHPOsFreeText: No wheelchair used, no respiratory support

    1. Case22: Female, 46 years report

      HPOsFreeText: 3 years of ERT completed, 6 Minute Walking Test at 73 meters, Forced Vital Capacity at 68%

      GenotypingMethod: GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 http://www.ncbi.nlm.nih.gov/clinvar/variation/4027

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.1819_1836del (p.Gly607_His612del )

      CAID: CA658795266 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.1819_1836del

      gnomAD: Not in gnomAD


      CaseAddInfo: Late Onset Pompe Disease

    2. Case11: Male, 57 years report

      HPOsFreeText: 9 years of ERT completed, 6 Minute Walking Test at 210 meters, Forced Vital Capacity at 31%

      GenotypingMethod: GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 http://www.ncbi.nlm.nih.gov/clinvar/variation/4027

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.525delT (p.Glu176Argfs*42)

      ClinVar: 4033 https://www.ncbi.nlm.nih.gov/clinvar/variation/4033/

      gnomAD: European (Non-Finnish) 1.880e-4, Overall 9.959e-5 http://gnomad.broadinstitute.org/variant/17-78078909-CT-C


      CaseAddInfo: Late Onset Pompe Disease

    3. Case18: Male, 66 years report

      HPOsFreeText: 9 years of ERT completed, 6 Minute Walking Test at 290 meters, Forced Vital Capacity at 45%

      GenotypingMethod: GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 http://www.ncbi.nlm.nih.gov/clinvar/variation/4027

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.1047del (p.Ser349Argfs)

      CAID: CA891862612 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.1047del

      gnomAD: Not in gnomAD


      CaseAddInfo: Late Onset Pompe Disease

    1. PD25

      Patient25: Male, Southern China

      CasePresentingHPOs:

      HPOsFreeText: IOPD

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: c.971dupC (p.Ser325GlufsX5) no ClinVar or CAID

      Variant2: NM_000152.4(GAA):c.1802C>T (p.Ser601Leu)

      ClinVar: 194154, https://www.ncbi.nlm.nih.gov/clinvar/variation/194154/

      gnomAD: n/a

    2. PD13

      Patient13: Female, Northern China

      CasePresentingHPOs:

      HPOsFreeText: IOPD

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.4(GAA):c.1802C>T (p.Ser601Leu)

      ClinVar: 194154, https://www.ncbi.nlm.nih.gov/clinvar/variation/194154/

      gnomAD: n/a

      Variant2: NM_000152.3:c.2411G>A

      CAID: CA401325125, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA401325125

      gnomAD: n/a

    3. PD05

      Patient5: Male, northern China

      CasePresentingHPOs:

      HPOsFreeText: IOPD

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo: homozygous

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant: NM_000152.4(GAA):c.2662G>T (p.Glu888Ter)

      ClinVar: 578595, https://www.ncbi.nlm.nih.gov/clinvar/variation/578595/

      gnomAD: 1.65e-05, http://exac.broadinstitute.org/variant/17-78092467-G-T

    1. 2

      Case2: Male, 18 years diagnosis, 1 year onset

      CasePresentingHPOs: HP:0009073, HP:0003198, HP:0003236, HP:0003327, HP:0008994 (Progressive proximal muscle weakness, Myopathy, Increased serum CK, Axial muscle weakness, Proximal muscle weakness in lower limbs)

      HPOsFreeText: Electromyography showed myogenic damage, Vacuolar myopathy, Serum CK is 1168.3 U/L

    1. P4

      Case#: Subject number 4, male, 5 months (onset), 34 months (first admission)

      DiseaseAssertion: Pompe disease

      FamilyInfo: "no family history of neuromuscular disorders"

      CasePresentingHPOs: HP:0001712 (left ventricular hypertrophy), HP:0002194 (delayed gross motor development), HP:0004887 (respiratory failure requiring assisted ventilation), HP:0002090 (pneumonia), HP:0002205 (recurrent respiratory infections), HP:0003819 (death in childhood)

      CaseHPOFreeText: ambulatory (transport ventilator), infantile-onset

      CaseNotHPOs:

      CaseNotHPOFreeText: no tracheostomy, no dysphagia at baseline, not on BiPAP

      CasePreviousTesting: “GAA activity in peripheral blood leukocytes lower than normal”; on enzyme replacement therapy

    1. PD21

      Patient21: Female, Northern China

      CasePresentingHPOs:

      HPOsFreeText: IOPD

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.4(GAA):c.1802C>T (p.Ser601Leu)

      ClinVar: 194154, https://www.ncbi.nlm.nih.gov/clinvar/variation/194154/

      gnomAD: n/a

      Variant2: NM_000152.3:c.1844G>T

      CAID: CA401369601, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA401369601

      gnomAD: n/a

    2. PD06

      Patient6: Male, northern China

      CasePresentingHPOs:

      HPOsFreeText: IOPD

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.4(GAA):c.1115A>T (p.His372Leu)

      ClinVar: 370483, https://www.ncbi.nlm.nih.gov/clinvar/variation/370483/

      gnomAD: n/a

      Variant2: NM_000152.3:c.2563G>C

      CAID: CA401326195, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA401326195

      gnomAD: 0.00003188, http://gnomad.broadinstitute.org/variant/17-78092073-G-C

    3. PD02

      Patient2: Female, northern China

      CasePresentingHPOs:

      HPOsFreeText: IOPD

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.4(GAA):c.2662G>T (p.Glu888Ter)

      ClinVar: 578595, https://www.ncbi.nlm.nih.gov/clinvar/variation/578595/

      gnomAD: 1.65e-05, http://exac.broadinstitute.org/variant/17-78092467-G-T

      Variant2: NM_000152.3:c.859-2A>T

      CAID: CA401363789, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA401363789

      gnomAD: n/a

    1. 35-year-old female

      Case1: Female, 33 years onset, 35 years report

      CasePresentingHPOs: HP:0030148, HP:0002094, HP:0001644, HP:0001712, HP:0006673, HP:0025168, HP:0030718, HP:0031295, HP:0001667, HP:0012667, HP:0006673, HP:0031185, HP:0002150, HP:0003165, HP:0008200, HP:0008208, HP:0002375, HP:0030232, HP:0004356, HP:0001685, HP:0040014, HP:0100295, HP:0001297 (Cardiac murmur, Dyspnea, Dilated cardiomyopathy, Left ventricular hypertrophy, Reduced systolic function, Left ventricular diastolic dysfunction, Right atrial enlargement, Left atrial enlargement, Right ventricular hypertrophy, Regional left ventricular wall motion abnormality, Reduced systolic function, Increased NT-proBNP level, Hypercalciuria, Elevated serum PTH, Primary hyperparathyroidism, Parathyroid hyperplasia, Hypokinesia, Increased sarcoplasmic glycogen, Abnormality of lysosomal metabolism, Myocardial fibrosis, Increased mitochondrial number, Muscle fiber atrophy, Stroke)

      HPOsFreeText: At 33 years patient had left ventricular ejection fraction (LVEF) of 35% (normal 54–76%), while 7 months later she had LV volume of 81 ml (systolic) and 127 ml (diastolic), LV mass index (2D) of 141 g/m2; LV septum thickness of 12 mm (normal 7–10 mm); LV posterior wall thickness of 9 mm (normal 7–11 mm); end-diastolic LV diameter of 55 mm (normal 39–53 mm), and LVEF of 34% and Liver longitudinal peak systolic strain of ~8% (normal < −18%); A subsequent MRI confirmed an LVEF of 32% (normal 54–85%), LV volume/Body Surface Area (BSA) of 91 ml/m2 (systolic, normal 12–36 ml/m2) and 134 ml/m2 (diastolic, normal 49–90 ml/m2), and LV mass/BSA of 66 g/m2 (diastolic, normal 59–103 g/m2); Extensive biventricular delayed myocardial enhancement predominantly in the epicardial and transmural muscles was noted; Pro-BNP level was elevated to 3,894 pg/ml; Histologic analysis of formalin-fixed tissue revealed prominent myocyte vacuolization that were dilled with glycogen; GAA activity was measured twice in dried blood spots - once with carrier levels and once with affected levels, however the GAA activity in skin fibroblasts (16.7% normal: 260±80 nmol/h/mg protein) and in heart biopsy tissue (0.07; normal: 0.89±0.42 μmol/min/g tissue) was clearly in the affected range and partially reduced in the muscle biopsy tissues (5.86; 38% of normal: 22.91±8.4 nmol/h/mg protein); Both muscle and heart tissue glycogen content and structure tested in the low or normal ranges (muscle glycogen content 0.11 umol glucose/mg tissue; normal 0.39–1.5; muscle glycogen structure measured as glucose-1-phosphate/glucose ratio 72.22%; normal > 5%; heart glycogen content 0.14 umol glucose/mg tissue; normal > 0.047; and heart glycogen structure 23.91%; normal > 5%); Urine glucose tetrasaccharides biomarker level was normal at 1.0 mmol/mol cr (<4); The patient was also noted to have elevation of calcium (11.6 mg/dl, reference 8.9–10.1 mg/dl) and PTH (541 pg/ml, reference 15–65 pg/ml); Skeletal muscle biopsy showed denervation atrophy; Several months after LVEF declined to 20–25% (normal 54–76%) with CK-MB being 36 U/l (normal 7.0–25.0 U/l); Patient had slightly weak back extensors and her 6-min walk test showed 76.9% predicted for her age and gender

      CaseNotHPOs: HP:0040081, HP:0002792, HP:0001324, HP:0002167, HP:0000157 (Abnormal levels of creatine kinase in blood, Reduced vital capacity, Muscle weakness, Speech impairment, Lingual abnormality)

      NotHPOsFreeText: Branching enzyme activity in the heart and muscle tissue was normal; Phosphofructokinase and myophosphorylase enzymatic activities were intact

      CaseAddInfo: No family history of cardiomyopathy or sudden death

    1. 7

      Case#: Patient 7, female, diagnosed 2013 (not given age of diagnosis), age 25 during study period

      DiseaseAssertion: Pompe Disease

      FamilyInfo: None given

      CasePresentingHPOs: None given

      CaseHPOFreeText: Requires wheelchair for long distance movement

      CaseNotHPOs: None given

      CaseNotHPOFreeText: None given

      CasePreviousTesting: None given

      Variant 1: NM_000152.5:c.-32-13T>G (unclear variant nomenclature)

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5:c.525del (unclear variant nomenclature)

      Variant 2 ClinVarID: N/A

      Variant 2 CAid: CA220406

      ParentalGenotype: Not provided

    1. to assess the potential effects of AMO treatment on GAA normal spliced mRNA expression and activity, as well as on the pathological phenotype in muscle cells, we obtained myoblasts from a LO-GSDII patient who presented the c.-32-13T > G mutation in compound heterozygosity with the c.2646_2646+1delTG mutation in exon 18

      Patient2: myoblasts from this patient were used to measure the effects of AMO tratment on GAA normal spliced mRNA expression/activity and the pathological phenotype in muscle cells. Under basal conditions, these myotubes retained 20% of enzymatic activity compared to WT. AMO treatment partially restored the correctly splice variant of GAA mRNA (confirmed via real-time PCR).

      CasePresentingHPOs:

      HPOsFreeText: LOPD

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting: n/a

      CaseGenotypingMethod: comparative DNA vs. mRNA sequencing

      Variant1: NM_000152.4(GAA):c.-32-13T>G

      Clinvar: 4027, https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: 0.003582, http://exac.broadinstitute.org/variant/17-78078341-T-G

      Variant2: NM_000152.3:c.2646_2647del

      CAID: CA913184745, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA913184745

      gnomAD: n/a

    1. 13

      Patient13: Male, 46yo at diagnosis, 47yo at ERT

      CasePresentingHPOs:

      HPOsFreeText: anti rh-GAA antibodies titre = 1:25,699, enzyme (μmol/g/h) = 0.52 (3-20)

      CaseNotHPOs:

      NotHPOsFreeText: NIV and mobility aid not required

      CaseAddInfo: 6yr disease duration, variants in trans

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.4(GAA):c.-32-13T>G

      Clinvar: 4027, https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: 0.003582, http://exac.broadinstitute.org/variant/17-78078341-T-G

      Variant2: NM_000152.3:c.482_483del

      CAID: CA8814879, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA8814879

      gnomAD: 1.729e-05, http://exac.broadinstitute.org/variant/17-78078864-TCC-T

    2. 16

      Patient16: Female, 37yo at diagnosis and ERT

      CasePresentingHPOs:

      HPOsFreeText: anti rh-GAA antibodies titre = neg, enzyme (μmol/g/h) = 0.18 (3-20), mobility aid required before and after ERT

      CaseNotHPOs:

      NotHPOsFreeText: NIV not required

      CaseAddInfo: 21yr disease duration

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant: NM_000152.4(GAA):c.-32-13T>G

      Clinvar: 4027, https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: 0.003582, http://exac.broadinstitute.org/variant/17-78078341-T-G

    1. Ten patients received concomitant immunomodulation (detailed in Supplementary Table S4); six were genotype-predicted as CRIM-negative, three were CRIM-positive, and one lacked genotype data.

      Patient 9 - homozygous

      Variant: NM_000152.4(GAA):c.2560C>T (p.Arg854Ter)

      ClinVar: 4034, https://www.ncbi.nlm.nih.gov/clinvar/variation/4034/

      gnomAD: 0.0002090, http://gnomad.broadinstitute.org/variant/17-78092070-C-T

    2. (Supplementary Table S3 shows details, IgG trajectories, and outcomes).

      Patient 14 -IOPD

      Variant1: NM_000152.3:c.1650dupG

      CAID: CA8815425, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.3%3Ac.1650dupG

      gnomAD: 0.000003992, http://gnomad.broadinstitute.org/variant/17-78085789-T-TG

      Variant2: NM_000152.4(GAA):c.2560C>T (p.Arg854Ter)

      ClinVar: 4034, https://www.ncbi.nlm.nih.gov/clinvar/variation/4034/

      gnomAD: 0.0002090, http://gnomad.broadinstitute.org/variant/17-78092070-C-T

    1. 6

      Case#: Patient 6

      DiseaseAssertion: Pompe Disease

      FamilyInfo: None given

      CasePresentingHPOs: None

      CaseHPOFreeText: None

      CaseNotHPOs: None

      CaseNotHPOFreeText: None

      CasePreviousTesting: Single gene sequencing with Ion Torrent Persional Genome Machine

      Glucosidase activity: 0.0 nmol 5MU/hr/mL

      Variant 1: NM_000152.5:c.1985del

      Variant 1 ClinVarID:

      Variant 1 CAid: CA658795269

      Variant 2: NM_000152.5:c.2446G>A

      Variant 2 ClinVarID: 92477

      Variant 2 CAid: CA145772

      ParentalGenotype: Not provided

    1. 4

      Case4: Female, 20 years onset, 48 years diagnosis, 57 years report, France

      CasePresentingHPOs: HP:0002540, HP:0002878, HP:0004887 (Inability to walk, Respiratory failure, Respiratory failure requiring assisted ventilation)

      HPOsFreeText: Lost ambulation at 42 years, Started invasive ventilation at 32 years, Started ERT given every other week at a dose of 20 mg/kg at 50 years for 87 months, Peak Anti-rhGAA antibodies at 1:25,600, FVC at 0.42/13 (L / % expected), MIP at 15 (cm H2O), MEP at 17 (cm H2O), Time off ventilation increased from 60 to 120 min, Total Motor Function Measure from 45 to 49, 6MWT from 10 to 30 meters

      CaseNotHPOs: HP:0030148 (Heart murmur)

      NotHPOsFreeText: No adverse reaction to ERT was recorded

      CaseAddInfo: Late Onset Pompe Disease